var title_f3_7_3184="Vocal cord injury intubation";
var content_f3_7_3184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vocal cord injury with endotracheal tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: a schematic view of the larynx with an endotracheal tube positioned between the vocal cords. Right: at laryngoscopy following extubation or tracheostomy, ulcers along the posterior aspects of both vocal cords are commonly seen as shown in this schematic. The site of these ulcers corresponds to the area where the translaryngeal endotracheal tube pressed against the vocal cords.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Colice, GL, Stukel, TA, Dain, B, Chest 1989; 89:877.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3184=[""].join("\n");
var outline_f3_7_3184=null;
var title_f3_7_3185="Scabies wrist infant";
var content_f3_7_3185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the wrist of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3185=[""].join("\n");
var outline_f3_7_3185=null;
var title_f3_7_3186="Stillbirth risk by GA";
var content_f3_7_3186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Hazard (risk) of stillbirth for singleton births without congenital anomalies by maternal age and gestational age, 2001-2002",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Older women experience an increased risk of stillbirth at all gestational ages, and this risk is magnified at term.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reddy, UM, Ko, CW, Willinger, M. Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am J Obstet Gynecol 2006; 195:764. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3186=[""].join("\n");
var outline_f3_7_3186=null;
var title_f3_7_3187="Bruise PI";
var content_f3_7_3187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    How bruises heal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 650px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows how a bruise changes color as it heals. A bruise starts off red in color (as shown in A) and then turns blue or purple (as shown in B). As a bruise heals, it can turn green and yellow (as shown in C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3187=[""].join("\n");
var outline_f3_7_3187=null;
var title_f3_7_3188="CRP levels outcome stenting";
var content_f3_7_3188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    C reactive protein predicts early adverse events after stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 727, increasing serum levels of C reactive protein (CRP) improved the ability to predict the 30 incidence of death or myocardial infarction when combined with increasing ACC/AHA lesion complexity score.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chew DP, Bhatt DL, Robbins MA, et al. Circulation 2001; 104:992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3188=[""].join("\n");
var outline_f3_7_3188=null;
var title_f3_7_3189="Pimecrolimus: Patient drug information";
var content_f3_7_3189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pimecrolimus: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     see \"Pimecrolimus: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/11/18612?source=see_link\">",
"     see \"Pimecrolimus: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elidel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elidel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise your chance of cancer. This drug is not for use in children younger than 2 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702741",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pimecrolimus or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a skin disease called Netherton's syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697153",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak immune system, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The chance of cancer is higher after using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use. This most often gets better within 5 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swollen gland.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Look of warts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not treating the skin on your hands, wash your hands after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug when health problem is gone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Restart this drug if signs show up again.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your signs do not get better after 6 weeks of care, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10974 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3189=[""].join("\n");
var outline_f3_7_3189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209930\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209931\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030616\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030618\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030617\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030622\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030623\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030625\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030620\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030621\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030626\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030627\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=related_link\">",
"      Pimecrolimus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/11/18612?source=related_link\">",
"      Pimecrolimus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_7_3190="Meconium ascites";
var content_f3_7_3190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59852%7EOBGYN%2F58207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59852%7EOBGYN%2F58207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meconium ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this 20 week fetus, fetal ascites is noted in the lower abdomen, adjacent to what appeared to be a markedly echogenic loop of bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen T Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meconium pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two weeks later, the ascites has resolved. The echogenic cystic area is still visible. After birth, imaging studies identified a meconium pseudocyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen T Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3190=[""].join("\n");
var outline_f3_7_3190=null;
var title_f3_7_3191="Oxycodone and acetaminophen: Pediatric drug information";
var content_f3_7_3191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone and acetaminophen: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=see_link\">",
"    see \"Oxycodone and acetaminophen: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/21/26965?source=see_link\">",
"    see \"Oxycodone and acetaminophen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Magnacet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Primlev&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade; 5/500;",
"     </li>",
"     <li>",
"      Tylox&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Novo-Oxycodone Acet;",
"     </li>",
"     <li>",
"      Oxycocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;-Demi;",
"     </li>",
"     <li>",
"      PMS-Oxycodone-Acetaminophen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=see_link\">",
"      see \"Oxycodone and acetaminophen: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Doses based on total oxycodone content; titrate dose to appropriate analgesic effects; maximum daily acetaminophen dose: 90 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     not to exceed 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesic; mild to moderate:",
"     </b>",
"     0.1-0.2 mg/kg/dose every 4-6 hours as needed; maximum oxycodone dose: 5 mg/dose  (American Pain Society, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesic, severe:",
"     </b>",
"     Initial dose: 0.2 mg/kg/dose every 4-6 hours as needed  (American Pain Society, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Analgesic:",
"     </b>",
"     Doses based on oxycodone content and should be given every 4-6 hours as needed and titrated to appropriate analgesic effects; maximum daily dose, based on acetaminophen content: 4 g/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate pain: Initial dose: 2.5-5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe pain: Initial dose: 10-30 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade; 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylox&reg;: 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg [contains sodium benzoate and sodium metabisulfite] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade;: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg per 5 mL (5 mL, 500 mL) [contains ethanol &lt;0.5%; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5/325: Oxycodone hydrochloride 2.5 mg and acetaminophen 325 mg; 5/325: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 5/325 [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magnacet&reg; 5/400: Oxycodone hydrochloride 5 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magnacet&reg; 10/400: Oxycodone hydrochloride 10 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 2.5/325: Oxycodone hydrochloride 2.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 5/325 [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 5/300: Oxycodone hydrochloride 5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 7.5/300: Oxycodone hydrochloride 7.5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 10/300: Oxycodone hydrochloride 10 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade; [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes caplet and solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F204999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food or milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to severe pain (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Endocet&reg; may be confused with Indocid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Percocet&reg; may be confused with Fioricet&reg;, Percodan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Roxicet&trade; may be confused with Roxanol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylox&reg; may be confused with Trimox, Tylenol&reg;, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F205002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See also individual agents: Allergic reaction, constipation, dizziness, dysphoria, euphoria, lightheadedness, nausea, pruritus, respiratory depression, sedation, skin rash, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone, acetaminophen, or any component; severe respiratory depression (in unmonitored settings or the absence of resuscitative equipment); suspected or known paralytic ileus",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with adrenal insufficiency (Addison&rsquo;s disease); biliary tract disease; pancreatitis; CNS depression/coma; acute alcoholism; delirium tremens; hypothyroidism (myxedema); severe liver, pulmonary, or renal impairment; urinary stricture; prostatic hypertrophy; or seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution when combining with other CNS depressants (eg, centrally acting antiemetics, general anesthetics, phenothiazines, sedative-hypnotics) as there may be additive CNS effects. If combined therapy is needed, consider reducing the dose of one or both agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although several case reports of acetaminophen-associated hemolytic anemia have been reported in patients with G-6-PD deficiency, a direct cause and effect relationship has not been well established (concurrent illnesses such as fever or infection may precipitate hemolytic anemia in patients with G-6-PD deficiency); therefore, acetaminophen is generally thought to be safe when given in therapeutic doses to patients with G-6-PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen may cause severe hepatotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day in adults). Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients. Do not exceed maximum daily doses; consider acetaminophen content of all products (prescription and OTC) including combination products when evaluating the total daily dose of acetaminophen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity  and anaphylactic reactions have been reported with acetaminophen  and oxycodone; use with caution in patients with hypersensitivity to other phenanthrene derivative opioid agonists (morphine, codeine, hydrocodone, hydromorphone, oxymorphone, levorphanol); discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oxycodone may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Respiratory depression may occur even at therapeutic dosages; use with extreme caution in patients with respiratory diseases including asthma, emphysema, COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. May cause hypotension; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics); may cause orthostatic hypotension in ambulatory patients. Oxycodone may obscure diagnosis or clinical course of patients with acute abdominal conditions; has been shown to decrease gastrointestinal motility; use with caution in postoperative patients especially after intra-abdominal surgery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms; warn patients of possible impairment of alertness or physical coordination; concurrent use of agonist/antagonist analgesics (ie, pentazocine, nalbuphine, and butorphanol) may precipitate withdrawal symptoms and/or reduce analgesic efficacy in patients following prolonged therapy with mu opioid agonists such as oxycodone. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting. High potential for abuse; healthcare providers should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains alcohol (&lt;0.5%).  Some preparations contain sodium metabisulfite which may cause allergic reactions in susceptible individuals; capsule may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of oxycodone and acetaminophen products containing sodium benzoate in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate of absorption of acetaminophen may be decreased when given with food high in carbohydrates",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of opioids during pregnancy may produce physical dependence in the neonate; respiratory depression may occur in the newborn if opioids are used prior to delivery (especially high doses).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, mental status, blood pressure; signs of misuse, abuse, and addiction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Inhibits the synthesis of prostaglandins in the CNS and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxycodone: Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/21/26965?source=see_link\">",
"      see \"Oxycodone and acetaminophen: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use if allergy to acetaminophen and/or opioid exists or if liver disease is present. Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause postural hypotension (use caution when changing positions from lying or sitting to standing); report the use of other prescription and nonprescription medications to your physician and pharmacist. May be habit-forming; do not discontinue abruptly if therapy lasts more than a few weeks; dose should be tapered to prevent narcotic withdrawal.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/7/3191/abstract-text/7614777 /pubmed\" id=\"7614777 \" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,\" 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12667 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3191=[""].join("\n");
var outline_f3_7_3191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135510\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204980\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054634\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054628\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204966\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204949\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204999\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054639\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054638\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205004\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205002\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054643\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054627\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054626\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204992\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204958\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054645\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204960\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054633\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054641\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054642\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054632\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=related_link\">",
"      Oxycodone and acetaminophen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/21/26965?source=related_link\">",
"      Oxycodone and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_7_3192="Physiology of insulin-like growth factor I";
var content_f3_7_3192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of insulin-like growth factor I",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3192/contributors\">",
"     David R Clemmons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3192/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3192/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/7/3192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-like growth factor-I (IGF-I) is a hormone that functions as the major mediator of growth hormone (GH)-stimulated somatic growth, as well as a mediator of GH-independent anabolic responses in many cells and tissues. IGF-I is a small peptide (molecular weight 7647) that circulates in serum bound to high affinity binding proteins. IGF-I is an unusual peptide in this regard, since it is more than 99 percent protein-bound.",
"   </p>",
"   <p>",
"    IGF-I is synthesized by multiple mesenchymal cell types. As a result, there are two major mechanisms of IGF-I regulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IGF-I that is synthesized in the liver and secreted into the blood is under the control of growth hormone (GH).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Autocrine/paracrine",
"      </span>",
"      IGF-I synthesized in peripheral tissues, such as bone. Its synthesis is controlled by GH and by factors that are secreted locally by the surrounding cell types. Since some of the",
"      <span class=\"nowrap\">",
"       autocrine/paracrine",
"      </span>",
"      IGF-I that is secreted enters into the systemic circulation, understanding the factors that regulate its synthesis is necessary to interpret changes in serum IGF-I concentrations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IGF-I exerts its effects via activation of the IGF-I receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/1\">",
"     1",
"    </a>",
"    ]. This receptor is widely distributed, which enables blood-transported IGF-I to coordinate balanced growth among multiple tissues and organs. In contrast,",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    IGF-I can stimulate local, unbalanced growth independently of systemic GH. Examples of this type of growth regulation are wound healing and growth of the contralateral kidney after unilateral nephrectomy.",
"   </p>",
"   <p>",
"    This review will cover the fundamental aspects of the control of IGF-I synthesis, secretion by tissues and cell types, transport of IGF-I in blood, the role of IGF-binding proteins, and regulation of IGF-I actions in target tissues. The physiology of growth hormone is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=see_link\">",
"     \"Physiology of growth hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IGF GENES AND STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IGF-I, IGF-II, and insulin genes are part of the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/2\">",
"     2",
"    </a>",
"    ]. The IGF-I gene is a complex, multicomponent gene with six exons, with the mature peptide being encoded by exons 3 and 4. Several forms of IGF-I mRNA are transcribed, including a 6 kb form that is regulated by growth hormone (GH).",
"   </p>",
"   <p>",
"    Mature IGF-I contains 70 amino acids, and IGF-II 67 amino acids. Proinsulin has a longer C-peptide region.",
"   </p>",
"   <p>",
"    IGF-I and -II contain D-domain extensions of eight and six amino acids, respectively, that are not cleaved, and are secreted as part of single chain proteins. Therefore, three dimensional analyses by NMR and x-ray crystallography as well as site-directed mutagenesis have revealed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tyrosines 24, 60, and, to some extent, 31 are critical for IGF-I receptor recognition. Phenylalanine 24 and valine 44 and arginine 36, 37, and 57 also are important [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The specific amino acids in the B domain in positions 3, 4, 15, and 16 are required for binding to any of the six forms of IGF binding proteins. Residues 49, 50, and 51 of the A domain are critical for recognition by four of the six IGF binding proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IGF-I RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IGF-I receptor (sometimes designated type 1 IGF receptor) is the primary mediator of the physiologic actions of IGF-I. The",
"    <span class=\"nowrap\">",
"     IGF-II/mannose-6-phosphate",
"    </span>",
"    receptor (type 2 IGF receptor) is of lesser importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     IGF-I receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IGF-I receptor is present in multiple cell types and tissues, which probably accounts for the ability of IGF-I to stimulate balanced, symmetric growth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/1\">",
"     1",
"    </a>",
"    ]. Receptor number is regulated by GH and thyroxine and is tightly controlled within a range of 20 to 35,000 receptors per cell. Other growth factors, such as platelet-derived growth factor (PDGF) and fibroblast growth factor, can also stimulate an increase the number of IGF-I receptors.",
"   </p>",
"   <p>",
"    The biochemical structure of the IGF-I receptor is similar to that of the insulin receptor and other growth factor receptors (",
"    <a class=\"graphic graphic_figure graphicRef81317 \" href=\"UTD.htm?24/10/24739\">",
"     figure 1",
"    </a>",
"    ). It is a heterotetrameric glycoprotein composed of two alpha subunits and two beta subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alpha subunit contains the IGF-binding domain and binds with an affinity constant of 10(-9) M for IGF-I; the affinity constant is sixfold lower for IGF-II, and 200- to 300-fold lower for insulin.",
"     </li>",
"     <li>",
"      The beta subunit contains a transmembrane domain followed by a tyrosine kinase (TK) domain. This domain contains an ATP-binding motif and a catalytic lysine at position 1003 that is required for TK activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Receptor activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligand binding to the receptor alpha subunit triggers a conformational change in the receptor, leading to autoactivation of TK activity, followed by autophosphorylation of six tyrosines, including a triple tyrosine motif at positions 1149, 1150, and 1151. Mutation of these tyrosines results in abolition of IGF-I signaling.",
"   </p>",
"   <p>",
"    The activated receptor phosphorylates insulin receptor substrate-1 and -2 (IRS-1 and -2), which are also phosphorylated by the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/4\">",
"     4",
"    </a>",
"    ]. Following phosphorylation, IRS-1 binds to the receptor at tyrosine 950. It then binds to adaptor proteins, such as Grb-2, or to other kinases, such as PI 3-kinase, which are activated. The receptor also can directly phosphorylate two other signaling proteins: Shc and Crk. Hybrid receptors containing an alpha-beta IGF half receptor paired with an alpha-beta insulin half receptor have been described. The physiologic significance of hybrid receptors is not well defined, but they may mediate the insulin-like actions of IGF-I.",
"   </p>",
"   <p>",
"    Following its tyrosine phosphorylation, IRS-1 binds to other signaling molecules through its Src homology 2 domains (",
"    <a class=\"graphic graphic_figure graphicRef74671 \" href=\"UTD.htm?7/56/8067\">",
"     figure 2",
"    </a>",
"    ). Grb-2 forms a complex with the Ras activating protein son of sevenless (SOS); this complex leads to p21 Ras activation, which activates downstream components of the mitogen activated protein kinase (MAP kinase) pathway (",
"    <a class=\"graphic graphic_figure graphicRef74671 \" href=\"UTD.htm?7/56/8067\">",
"     figure 2",
"    </a>",
"    ). Activation of this pathway is important for stimulation of cell growth by IGF-I. The IGF-I receptor can also phosphorylate a signaling protein termed Shc. Like phosphorylated IRS-1, Shc can bind to Grb-2 and activate the RAS-MAP kinase pathway leading to stimulation of cell growth.",
"   </p>",
"   <p>",
"    IRS-1 activation also leads to activation of PI 3-kinase. This generates inositol triphosphate and activation of protein tyrosine kinase-B. This kinase can activate mTOR,",
"    <span class=\"nowrap\">",
"     p70/S6",
"    </span>",
"    kinase and GSK-3&beta;, which are important for stimulation of protein synthesis and glucose transport. This pathway is also important for IGF-I stimulation of cell motility and inhibition of apoptosis.",
"   </p>",
"   <p>",
"    An important function of IGF-I receptor induced signaling appears to be the prevention of apoptosis. When cells in culture have been stimulated to undergo apoptosis, the presence of IGF-I can rescue them from activating downstream signaling components of the apoptotic pathway.",
"   </p>",
"   <p>",
"    Receptor overexpression (eg, cells expressing &gt;1,000,000 receptors per cell) can result in cell transformation, ie, the ability of cells to form tumors when injected into mice. However, this degree of increase in receptor number is rarely detected in human tumors. Overexpression of the IGF-I receptor can also abrogate the requirement of tumor cells for exposure to other growth factors, such as PDGF and epidermal growth factor (EGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/5\">",
"     5",
"    </a>",
"    ]. Certain oncogenes that lead to cellular transformation, such as Src, require the presence of an intact IGF-I receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/5\">",
"     5",
"    </a>",
"    ]. The role of modest increases in IGF-I receptor number in oncogenesis is an area of active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     IGF-II/mannose 6 phosphate receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     IGF-II/mannose-6-phosphate",
"    </span>",
"    receptor is less important for growth stimulation but is important for regulation of IGF-I and -II activities, by both sequestering the hormones and promoting their degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/7\">",
"     7",
"    </a>",
"    ]. Its structure is different from the IGF-I receptor, being a single chain protein that also binds avidly to mannose-6-phosphate residues on lysosomal enzymes. The receptor binds IGF-II with an 80-fold greater affinity than IGF-I and does not bind to insulin. It is rapidly endocytosed and recirculates from endosomes back to the cell surface, a process that is stimulated by insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IGF BINDING PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IGF binding proteins (IGFBPs) are a family of six high-affinity proteins whose affinities for IGF-I and -II are greater than the IGF-I receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/8\">",
"     8",
"    </a>",
"    ]. One or more members of this family are present in all extracellular fluids and they control the ability of IGF-I and -II to bind to receptors. In most cases, less than 1 percent of the total IGF-I in plasma is in an unbound state.",
"   </p>",
"   <p>",
"    A major function of the IGFBPs is to transport IGF. They control access to the extravascular space, as well as tissue localization and distribution. IGFBP-3 is the most abundant form in plasma with the highest affinity for IGF-I, and is in a saturated state. IGFBP-2 is the second most abundant binding protein. Although present in lower concentrations, IGFBP-1 can account for the greatest changes in free IGF-I, since it is usually unsaturated and its levels can fluctuate as much as fivefold during a 24-hour period.",
"   </p>",
"   <p>",
"    The structures of the six IGFBPs show a great deal of similarity. A major conservation of sequence is present in the N&ndash; and C-terminal domains of each protein. The IGF binding site for IGFBP-3 and -5 has been localized to a hydrophobic patch that occurs in the latter part of the amino terminus. This region is also conserved in IGFBP-1, -2, -4, and -6.",
"   </p>",
"   <p>",
"    High affinity binding requires this site, as well as correct folding of a critical region in the C-terminus, which apparently aligns with the N-terminal site. The mid-region that connects the N&ndash; and C-terminal domains is a site of proteolytic cleavage, which results in loss of IGF-I binding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Structural differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their common features, some unique features are present in each of these proteins. These specific features account for some differences in physiologic function that have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IGFBP-1 contains an Arg-Gly-Asp sequence near its amino terminus. This allows it to bind to the alpha-5-beta-1 integrin; such binding appears to stimulate cell migration and inhibit protein breakdown.",
"     </li>",
"     <li>",
"      IGFBP-2 also contains an Arg-Gly-Asp sequence near its C-terminus, but it does not appear to bind to alpha-5-beta-1 integrin. It contains a unique",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      binding domain in the linker region that mediates its binding to cell surfaces.",
"     </li>",
"     <li>",
"      IGFBP-3 is N-glycosylated and is the major IGF binding moiety in plasma as more than 75 percent of circulating IGF-I is bound to this protein. IGFBP-3 concentrations are increased by GH administration, and it functions as the major GH responsive carrier of IGF-I and IGF-II. IGFBP-3 binds to another plasma protein, acid labile subunit (ALS), which prolongs its half-life and stabilizes IGF-I binding to this ternary complex in plasma, increasing its half-life to 16 hours.",
"     </li>",
"     <li>",
"      IGFBP-4 often inhibits IGF activity. It is cleaved by proteases that are present in many extracellular fluids. This renders it unable to bind IGF-I and -II.",
"     </li>",
"     <li>",
"      IGFBP-5 binds to extracellular matrix (ECM), which lowers its affinity for IGF-I eightfold. This allows ECM-associated IGFBP-5 to potentiate, rather than inhibit, IGF-I activity by releasing free IGF-I in the extracellular space. IGFBP-5 is rapidly cleaved in most physiologic fluids to a non-IGF binding 22 kDa fragment.",
"     </li>",
"     <li>",
"      IGFBP-6 is O-glycosylated. It appears to be inhibitory in most biologic test systems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Regulation of plasma IGFBPs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma concentrations of IGFBP-3 and acid labile subunit (ALS) are increased by GH, as is IGF-I (see",
"    <a class=\"local\" href=\"#H10\">",
"     'IGFBP-3'",
"    </a>",
"    below). Each component of this ternary complex maintains the half-life of the other components, resulting in greater stabilization (eg, 16 hours for the tertiary complex).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     IGFBP-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, IGFBP-3 is the most abundant plasma IGFBP, followed by IGFBP-2 and -1. ALS and IGF-I are the most GH-dependent gene products, although there is also some increase in IGFBP-3. Other hormones, such as testosterone, estrogen, and thyroxine, also regulate IGFBP-3 synthesis. Plasma IGFBP-3 is reduced in deficiency states of each of these three hormones and returns to normal if replacement therapy is given.",
"   </p>",
"   <p>",
"    Another important variable that controls the plasma IGFBP-3 concentration is proteolysis. A protease in human pregnancy serum rapidly degrades IGFBP-3 into non-IGF-I binding fragments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     IGFBP-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The affinity of IGFBP-2 for IGF-I is substantially less than that of IGFBP-3, and IGFBP-2 has a much shorter half-life (90 minutes versus 16 hours). This explains why more than 75 percent of circulating IGF-I is bound to IGFBP-3. However, IGFBP-2 has an important function in that it rapidly regulates the amount of free IGF-I that is available to enter the extravascular space and bind to receptors in peripheral tissues. IGFBP-2 can cross the capillary wall and may provide a transport vehicle for IGF-I out of the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/9\">",
"     9",
"    </a>",
"    ]. IGFBP-2 plays a role in hematopoietic cell proliferation and acquisition of normal bone mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    IGFBP-2 concentrations are decreased in response to GH or insulin. IGFBP-2 is also increased in response to IGF-I administration to humans. Nutritional restriction results in an increase in IGFBP-2 and a reduction in free IGF-I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     IGFBP-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentration of IGFBP-1 is acutely regulated by insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/10\">",
"     10",
"    </a>",
"    ]. Plasma IGFBP-1 is increased five- to sixfold by fasting, which inhibits insulin release, and it is reduced by feeding or the administration of insulin. The net effect is that IGFBP-1 levels fluctuate widely during a 24-hour period, depending upon food intake. This results in major changes in free IGF-I, since IGFBP-3 and -2 levels fluctuate much less. Although the amount of IGF binding capacity that changes in response to meals is small, the amount of free IGF-I is also small; thus, a large percentage of the free fraction of IGF-I can be altered in response to small changes in total IGF binding capacity.",
"   </p>",
"   <p>",
"    Administration of IGFBP-1 to animals results in increased glucose concentrations, suggesting that it may have a glucoregulatory function. Plasma IGFBP-1 values have been used as a marker of hepatic insulin sensitivity, being elevated in insulin resistant states. They increase progressively over time in individuals who develop type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     IGFBP-4 and -5",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGFBP-4 concentrations in serum are quite low, and correlate with the ability of parathyroid hormone to alter bone turnover. IGFBP-5 can also form a tertiary complex with acid labile subunit and its plasma concentrations are regulated by GH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     REGULATION OF CIRCULATING IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the source of most (75 percent) of plasma IGF-I, as proven by organ specific gene targeting studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/12\">",
"     12",
"    </a>",
"    ]. Variables that regulate synthesis and release by the liver, primarily GH, also regulate its plasma concentrations. Variables that regulate serum IGFBP-3 can also have major effects on IGF-I concentrations.",
"   </p>",
"   <p>",
"    Plasma IGF-I levels rise sevenfold from very low concentrations at birth (20 to 60",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    to peak values at puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/13\">",
"     13",
"    </a>",
"    ]. Concentrations then fall rapidly in the second decade, reaching values that are 40 to 50 percent of the maximum pubertal levels by age 20. They then decline slowly by an additional 50 percent up to age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/14\">",
"     14",
"    </a>",
"    ]. Part of this change is due to age-dependent changes in GH secretion.",
"   </p>",
"   <p>",
"    There is also an important genetic determinant of plasma IGF-I. Twin studies have shown that approximately 40 percent of each individual's IGF-I variability can be accounted for by undefined genetic factors that are linked to final adult height. Several polymorphisms in the IGF-I gene have been identified and they account for some of the variability in IGF-I concentrations in the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone is a major determinant of plasma IGF-I, and GH-deficient children have plasma IGF-I concentrations that are often below the 95 percent confidence interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis of growth hormone deficiency in children\", section on 'IGF-I and IGFBP-3'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of GH on plasma IGF-I are complex. Although it stimulates IGF-I gene transcription and secretion by the liver, part of the increase is controlled by concurrent stimulation of IGFBP-3 and ALS. Together, these three proteins form a stable ternary complex; any factor that attenuates the relative increase in any one of the three components will produce a major reduction in serum IGF-I.",
"   </p>",
"   <p>",
"    Administration of GH to GH-deficient subjects results in a six- to sevenfold increase in IGF-I concentrations. Mean IGF-I values in acromegaly are seven times the normal age-adjusted mean [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/16\">",
"     16",
"    </a>",
"    ], and the severity of the IGF-I abnormality correlates with the amount of soft tissue growth. It also correlates with the amount of GH secretion in acromegaly, up to mean 24-hour GH values of 20",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional status is an important determinant of plasma IGF-I. Minimum intakes of 20",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day of energy and 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of protein are necessary to maintain normal plasma values. Fasting for seven days results in a 50 percent decrease in plasma IGF-I values. A decline is also seen in diseases associated with malnutrition, such as hepatic failure, inflammatory bowel disease, and renal failure. Much but not all of the change in IGF-I levels is mediated by a malnutritioned-linked decrease in GH sensitivity and to some extent GH receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma IGF-I is reduced in hypothyroidism and increases with T4 replacement. In comparison, estrogen has minimal effects on plasma IGF-I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     REGULATION OF TISSUE IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, IGF-I is synthesized in peripheral tissues, as well as the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/17\">",
"     17",
"    </a>",
"    ], and peripheral tissue synthesis contributes to plasma concentrations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone and cartilage are two important skeletal sources of IGF-I mRNA. PTH regulates IGF-I gene transcription in bone. GH also increases IGF-I synthesis by osteoblasts and chondrocytes, suggesting this local synthesis contributes to growth regulation.",
"     </li>",
"     <li>",
"      Erythroid cell precursors synthesize IGF-I in response to erythropoietin.",
"     </li>",
"     <li>",
"      IGF-I expression is regulated in the ovary, and FSH administration increases IGF-I concentrations in follicular fluid.",
"     </li>",
"     <li>",
"      IGF-I crosses the blood-brain barrier to a limited extent. As a result, local synthesis, which occurs in the central nervous system, provides an important source of IGF-I.",
"     </li>",
"     <li>",
"      IGF-I is synthesized in satellite cells and myoblasts in skeletal muscle. Following injury there is a wave of IGF-I synthesis that correlates with reparative cell division [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/18\">",
"       18",
"      </a>",
"      ]. IGF-I synthesis is also increased during muscle hypertrophy, particularly in models of cardiac hypertrophy due to pressure overload.",
"     </li>",
"     <li>",
"      The kidney is an important local source of IGF-I. Following unilateral nephrectomy during compensatory growth, there is a major increase in IGF-I mRNA expression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MAJOR PHYSIOLOGIC EFFECTS OF IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of experimental model systems have been utilized to analyze the actions of IGF-I in vivo: administration of purified IGF-I to whole animals, deletion of IGF-I gene expression or overexpression of IGF-I in transgenic mouse models, and administration of IGF-I to humans.",
"   </p>",
"   <p>",
"    In addition, tissue-specific deletion of IGF-I synthesis has been utilized to study the contribution of specific organs to maintaining serum IGF-I concentrations or to localized growth regulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Whole animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;When administered to hypophysectomized animals, IGF-I stimulates balanced growth in all tissues. A rate limiting factor for the ability of IGF-I to stimulate growth is the induction of hypoglycemia. This results in major limitations on the amount of IGF-I that can be given to animals. If hypoglycemia is avoided, then administration of IGF-I will mimic the effect of GH on linear growth.",
"   </p>",
"   <p>",
"    IGF-I administration can also reverse the catabolic effect of nutrient deprivation or administration of glucocorticoids. In addition, IGF-I increases wound healing, raises the glomerular filtration rate, and stimulates whole body protein accretion. Infusion of IGF-I into insulin-deficient diabetic rats results in improved growth and improved utilization of glucose.",
"   </p>",
"   <p>",
"    If IGFBP-3 is administered with IGF-I, there is enhanced bone mineralization and increased linear growth compared to administration of IGF-I alone. Part of this effect of concomitant administration of IGFBP-3 is that hypoglycemia is not induced; as a result, high concentrations of IGF-I can be achieved, which result in better growth stimulation compared with the lower concentrations that are attained with IGF-I alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transgenic animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animals in which GH expression has been deleted, expression of the IGF-I transgene results in stimulation of balanced growth, and if adequate expression of IGF-I is achieved, growth is equal to animals that receive GH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/19\">",
"     19",
"    </a>",
"    ]. If the transgene is variably expressed, then organ growth may not be symmetric. For example, mice that have expression predominantly in pancreas, kidney, and brain have greater increases in the size of these organs.",
"   </p>",
"   <p>",
"    Homologous recombination experiments have been useful in determining the effects of IGF-I on somatic growth. As an example, animals in which the IGF-I gene is completely deleted have fetal growth retardation (60 percent of normal birth weight and length) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/20\">",
"     20",
"    </a>",
"    ]. They grow poorly after birth, and only 10 to 20 percent of these animals survive to adulthood. If the IGF-I receptor is deleted, then at birth the animals are 45 percent of normal size, and they die immediately due to inadequate development of skeletal muscle in the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If IGF-I gene expression is deleted only in the liver, the animals are born normal size but have only 25 percent of the normal serum IGF-I concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/10\">",
"     10",
"    </a>",
"    ]. In striking contrast to animals with total IGF-I deletion, these animals grow at a near normal rate postnatally (approximately 6 to 8 percent growth retardation). If peripherally synthesized IGF-I is eliminated and hepatic synthesis is retained, growth is also retarded [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, both",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    IGF-I and liver-derived IGF-I are important for normal postnatal growth, and genetic studies show that they contribute equally to final height [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In terms of glucose metabolism, animals with total IGF-I deletion have not been analyzed in detail. However, they are not overtly hyperglycemic and do not require insulin administration to maintain a normal blood glucose. Animals in which IGF-I gene expression has been deleted in the liver are also normoglycemic and respond normally to a glycemic stimulus. However, they are insulin resistant and insulin administration does not reduce glucose to the same extent as in control animals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When tyrosine phosphorylation of the insulin receptor was examined in skeletal muscle, the animals showed impaired responsiveness to insulin, both in terms of phosphorylation of the insulin receptor and stimulation of IRS-1 phosphorylation. This suggests that lowering plasma IGF-I concentration induces insulin resistance in muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Effects of IGF-I administration to humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGF-I infusion into calorically restricted humans restores nitrogen balance to normal. Similarly, coadministration of GH and IGF-I induces positive nitrogen balance in calorically restricted humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/23\">",
"     23",
"    </a>",
"    ]. The effect that is achieved is substantially greater than that seen with IGF-I alone, probably because GH also stimulates an increase in serum IGFBP-3. Other effects of IGF-I administration include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in blood glucose if sufficient concentrations are given [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A threefold increase in IGFBP-2 concentrations and a 25 percent increase in glomerular filtration rate.",
"     </li>",
"     <li>",
"      Stimulation of whole body protein synthesis, and inhibition of proteolysis. The combination of GH plus IGF-I has a greater effect on protein synthesis compared with IGF-I alone.",
"     </li>",
"     <li>",
"      Partial reversal of the catabolic effect of glucocorticoids on protein synthesis.",
"     </li>",
"     <li>",
"      An anabolic effect on bone, as demonstrated by increases in markers of bone formation in patients with low bone mineral density who receive IGF-I. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Growth factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of IGF-I to patients with type 2 diabetes results in a 3.4-fold improvement in insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/24\">",
"     24",
"    </a>",
"    ]. Whether subjects are receiving insulin or oral hypoglycemic agents, mean glucose can be improved substantially in diabetics who receive IGF-I injections.",
"   </p>",
"   <p>",
"    Injections of free IGF-I also causes dose-dependent side effects, which include retinal edema, Bell's palsy, and severe myalgias. The frequency of these side effects can usually be reduced if IGF-I doses of 40",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    BID or less are administered [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/25\">",
"     25",
"    </a>",
"    ]. IGF-I is not currently approved for treatment of type 2 diabetes, but it has been used effectively for blood glucose control in rare patients with extreme insulin resistance syndromes.",
"   </p>",
"   <p>",
"    IGF-I therapy is effective in patients with GH insensitivity due to GH receptor mutations and in patients with short stature and very low serum IGF-I (eg, &lt;2.5 SDS). Adverse effects, such as enhanced growth of tonsils, facial soft tissue, and kidneys, have been seen in some children. Currently, IGF-I therapy is approved for children with short stature (&lt;-3.0 SDS) or IGF-I level that is &lt;-3.0 SDS and normal to elevated GH levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION OF IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGF-I is a potent stimulator of DNA synthesis in vitro. Most cell types in culture possess IGF-I receptors and respond to its addition by increases in DNA and protein synthesis, and cell size [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/26\">",
"     26",
"    </a>",
"    ]. During normal physiologic conditions, the IGF-I receptor is the major indicator of IGF-I actions.",
"   </p>",
"   <p>",
"    Following IGF-I binding to its receptor, the receptor undergoes a conformational change that activates its tyrosine kinase (TK) activity. The TK autophosphorylates tyrosines, which act as docking sites for the signaling proteins Shc and IRS-1 or IRS-2. The IRS proteins are phosphorylated by the receptor TK then bind to the p85 subunit of the PI-3 kinase leading to activation of protein kinase B and stimulation of protein synthesis as well as inhibition of apoptosis. The signaling protein Shc is also phosphorylated, enabling it to bind to Grb-2, which leads to activation of MAP kinase and stimulation of DNA synthesis and cell growth. IGF-I has also been shown in vitro to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stimulate multiple metabolic reactions that are important for carbohydrate metabolism, such as glucose transport, glucose oxidation, and lipid synthesis.",
"     </li>",
"     <li>",
"      Act as a cell cycle regulatory growth factor; unlike PDGF or FGF, IGF-I usually does not stimulate quiescent cells to enter the G1 phase of the cell cycle. However, once cells have entered the G1 phase, it is an important factor for progression to \"S\" phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In several injury models, there is a major increase of IGF-I synthesis by the cell types that will repair the injury. This secreted IGF-I then binds to the same cell or adjacent cells and stimulates DNA synthesis in reparative cell types. This has been shown for fibroblasts, endothelium, cartilage, smooth muscle, skeletal muscle, and neural tissue.",
"   </p>",
"   <p>",
"    IGF-I also has a number of other actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some systems, IGF-I is a potent inhibitor of apoptosis, particularly hematopoietic and neuronal systems. In many tumor cell types, IGF-I is required for inhibition of apoptosis. As an example, during development, IGF-I is a potent inhibitor of neuronal, myocyte, and oligodendrocyte cell death. During follicular development, IGF-I stimulation by gonadotropins prevents apoptosis of developing cells within the follicle.",
"     </li>",
"     <li>",
"      IGF-I induces the expression of myogenin in skeletal muscle. Any decrease in autocrine-produced IGF-I will inhibit this process. Time dependent, specific exposure of L6 myoblasts to IGF-I results in stimulation of differentiation at critical time points. In addition, differentiation markers are induced by IGF-I in osteoclasts, chondrocytes, and neural cells.",
"     </li>",
"     <li>",
"      IGF-I stimulates specialized functions in endocrine tissues, including enhancement of the effects of FSH and LH on production of steroids by ovarian granulosa cells, testosterone secretion by Leydig cells, the effects of ACTH on adrenal cortical cell steroidogenesis, and the response of thyroid follicular cells to TSH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In pathophysiologic states, tissue sensitivity to IGF-I can be altered. For example, during hyperglycemia, certain cell types, such as vascular cells, have enhanced sensitivity to IGF-I. This is due to a change in signal transduction in which a transmembrane protein SHPS-1 is activated in response to hyperglycemia and IGF-I receptor stimulation. This results in increased activation of the MAP and PI-3 kinase pathways via an IRS-1-independent mechanism, a change that may be important in the development of diabetic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3192/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-like growth factor-I (IGF-I) is a small peptide that circulates in serum bound (more than 99 percent) to high affinity binding proteins. IGF-I is synthesized by multiple mesenchymal cell types. There are two major sources of IGF-I: circulating IGF-I that is synthesized in liver and secreted into the blood, and",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    IGF-I synthesized in peripheral tissues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IGF-I receptors &ndash; The IGF-I receptor is the primary mediator of the physiologic actions of IGF-I. The IGF-I receptor is present in multiple cell types and tissues, which probably accounts for the ability of IGF-I to stimulate balanced, symmetric growth. Receptor number is regulated by GH and thyroxine and is tightly controlled within a range of 20 to 35,000 receptors per cell. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'IGF-I receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IGF binding proteins &ndash; The IGF binding proteins (IGFBPs) are a family of six high-affinity proteins whose affinities for IGF-I and -II are greater than the IGF-I receptor. One or more members of this family are present in all extracellular fluids and they control the ability of IGF-I and -II to bind to receptors. In most cases, less than 1 percent of the total IGF-I in plasma is in an unbound state. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'IGF binding proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of circulating IGF-I &ndash; The liver is the source of most (75 percent) of plasma IGF-I. Variables that regulate synthesis and release by the liver, primarily GH, also regulate its plasma concentrations. Nutritional and thyroid status also affect plasma IGF-I. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Regulation of circulating IGF-I'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of tissue IGF-I &ndash; IGF-I is synthesized in peripheral tissues, as well as the liver, and peripheral tissue synthesis contributes to plasma concentrations. Its regulators are described above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Regulation of tissue IGF-I'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effects of IGF-I in humans &ndash; IGF-I therapy is effective (and approved for clinical use) in children with GH insensitivity due to GH receptor mutations, and in children with short stature and very low serum IGF-I. Other potential effects of IGF-I administration are described above (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Effects of IGF-I administration to humans'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/1\">",
"      Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/2\">",
"      Adamo ML, Neuenschwander S, LeRoith D, Roberts CT Jr. Structure, expression, and regulation of the IGF-I gene. Adv Exp Med Biol 1993; 343:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/3\">",
"      Denley A, Cosgrove LJ, Booker GW, et al. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005; 16:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/4\">",
"      Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004; 27:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/5\">",
"      Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol 2009; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/6\">",
"      Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009; 115:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/7\">",
"      Brown J, Jones EY, Forbes BE. Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci 2009; 34:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/8\">",
"      Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/9\">",
"      DeMambro VE, Clemmons DR, Horton LG, et al. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 2008; 149:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/10\">",
"      Murphy LJ. The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Exp Diabesity Res 2003; 4:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/11\">",
"      Kotronen A, Lewitt M, Hall K, et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 2008; 93:4867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/12\">",
"      Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999; 96:7324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/13\">",
"      Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/14\">",
"      Brabant G, von zur M&uuml;hlen A, W&uuml;ster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003; 60:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/15\">",
"      Ester WA, Hokken-Koelega AC. Polymorphisms in the IGF1 and IGF1R genes and children born small for gestational age: results of large population studies. Best Pract Res Clin Endocrinol Metab 2008; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/16\">",
"      Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/17\">",
"      Butler AA, Le Roith D. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 2001; 63:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/18\">",
"      Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 2007; 7:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/19\">",
"      Behringer RR, Lewin TM, Quaife CJ, et al. Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology 1990; 127:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/20\">",
"      Lupu F, Terwilliger JD, Lee K, et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/21\">",
"      Stratikopoulos E, Szabolcs M, Dragatsis I, et al. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A 2008; 105:19378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/22\">",
"      Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004; 113:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/23\">",
"      Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/24\">",
"      Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006; 6:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/25\">",
"      Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 2009; 25:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/26\">",
"      Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006; 1766:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3192/abstract/27\">",
"      Clemmons DR, Maile LA. Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 2003; 144:1664.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3801 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3192=[""].join("\n");
var outline_f3_7_3192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IGF GENES AND STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IGF-I RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IGF-I receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Receptor activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IGF-II/mannose 6 phosphate receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IGF BINDING PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Structural differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Regulation of plasma IGFBPs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - IGFBP-3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - IGFBP-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - IGFBP-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - IGFBP-4 and -5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      REGULATION OF CIRCULATING IGF-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      REGULATION OF TISSUE IGF-I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MAJOR PHYSIOLOGIC EFFECTS OF IGF-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Whole animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transgenic animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Effects of IGF-I administration to humans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MECHANISMS OF ACTION OF IGF-I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/3801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/3801|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/10/24739\" title=\"figure 1\">",
"      IGF1 and insulin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/56/8067\" title=\"figure 2\">",
"      Mechs of IGF-1 receptor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=related_link\">",
"      Physiology of growth hormone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_7_3193="Diagnostic imaging of joint pain";
var content_f3_7_3193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic imaging of joint pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Barbara N Weissman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Steven J Baccei, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3193/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/7/3193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pain may be due to a broad array of conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/1\">",
"     1",
"    </a>",
"    ]. Imaging studies of the joint, in combination with clinical evaluation, are often helpful in establishing a specific diagnosis. The choice of imaging procedure is based on the clinical situation, different diagnostic considerations, and the availability of specific imaging modalities. Guidelines for imaging for specific clinical situations are available in the American College of Radiology appropriateness criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sufficient history should be provided to assist the radiologist in study interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the quality and location of pain, a history of trauma, pertinent medical history, and laboratory data are invaluable information when interpreting an imaging study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the use of the diagnostic imaging modalities and techniques to evaluate joint pain is presented here. Detailed discussions of these techniques in specific diseases are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography remains the initial imaging choice in many, if not most, bone and joint disorders. Radiography utilizes an x-ray tube with a two-dimensional image detector, traditionally a sheet of film. In many of today's radiology departments, radiographic images are digital and thus interpreted on a computer display. Two systems are available to produce digital projection radiographs, computed radiography and digital radiography.",
"   </p>",
"   <p>",
"    Computed radiography (CR) was introduced commercially in the early 1980s. In a CR system, a photostimulable storage phosphor screen acts as the detector that interacts with the x-ray image to produce a (stored) latent image; a laser light is used to stimulate the phosphor particles to luminesce, thus extracting the latent image from the screen. The image is then converted into a digital image [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/5\">",
"     5",
"    </a>",
"    ]. In CR, traditional film cassettes are replaced by storage phosphor cassettes and chemical processing is replaced by CR readers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/5\">",
"     5",
"    </a>",
"    ]. The images can be printed onto film or transmitted to a PACS (picture archiving and communication system) workstation.",
"   </p>",
"   <p>",
"    Digital Radiography (DR), introduced in the 1990s, refers to devices in which the digitization of the x-ray signal takes place within the detector itself. This approach provides an immediate full-fidelity image on a display monitor. Detection devices can use either a direct or an indirect conversion mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both CR and DR systems provide greater latitude than film screen systems, and decrease the number of examinations that need to be repeated. The advantages of direct radiography include increased productivity and equivalent or better image quality at potentially lower radiation dose to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/7\">",
"     7",
"    </a>",
"    ]. Images are rapidly available for checking image quality and for interpretation, and systems can be networked for easy distribution of images.",
"   </p>",
"   <p>",
"    The expense of installing CR or DR equipment and portability are both disadvantages of digital radiography. DR systems coupled with a PACS allow images to be captured, stored, reviewed, interpreted and distributed within minutes. DR systems are most often installed in high volume areas whereas CR systems can provide digital imaging to lower volume areas at decreased expense as well as provide a mechanism for capturing difficult examinations such as bedside portables.",
"   </p>",
"   <p>",
"    No matter what display methods are used, a minimum of two radiographic projections at right angles are usually obtained to fully appreciate the area of interest since abnormalities can potentially be obscured by superimposition. Standardized imaging protocols are used for most joints. Radiographic examination is relatively inexpensive, rapid, and nearly universally available.",
"   </p>",
"   <p>",
"    Radiographs have the greatest resolution of all currently available imaging modalities. Densities that can be distinguished on radiographs are calcium, soft tissue, fat, and air. Radiography is especially useful for detecting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evaluating:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures",
"     </li>",
"     <li>",
"      Periosteal reaction",
"     </li>",
"     <li>",
"      Faint soft tissue calcification or ossification",
"     </li>",
"     <li>",
"      Localized lesions of bone",
"     </li>",
"     <li>",
"      Failure or complication of orthopedic hardware",
"     </li>",
"     <li>",
"      Bone dysplasias and other skeletal deformities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fluoroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a \"real-time\" radiographic imaging modality, fluoroscopy can be used to observe the motion of joints and to guide proper needle insertion into deep-seated joints, such as the hip or sacroiliac joint [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/8\">",
"     8",
"    </a>",
"    ]. It may also accurately detect focal cortical disease, fractures, and ligamentous instability, as the patient can be optimally positioned or a specific joint mechanically stressed under real-time imaging.",
"   </p>",
"   <p>",
"    Radiographic magnification is not routinely used. However, it can be helpful by clearly demonstrating the presence of small erosions, cortical resorption, chondrocalcinosis, or periostitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, radiographic examinations show soft tissues (eg, muscles, cartilage, joint fluid, menisci) to be the same density and, therefore, to be indistinguishable from one another. Arthrography refers to imaging following the injection of contrast material into a joint and is often performed with fluoroscopic guidance. The boundary between contrast and soft tissue structures makes the surfaces of intraarticular structures more distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using sterile technique, and local anesthesia, the joint space is entered. Synovial fluid may be aspirated for diagnostic purposes. &nbsp;Next, a contrast agent, such as iodinated contrast, is typically injected. However, in patients who are not able to tolerate contrast, primarily because of allergy, air can be injected into the joint to serve as a contrast agent.",
"   </p>",
"   <p>",
"    Lastly, medication (typically anesthetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoid) can be injected into the joint therapeutically.",
"   </p>",
"   <p>",
"    Arthrography facilitates identification of intraarticular (loose) bodies, ligament or tendon injuries, synovial or cartilage abnormalities, sinus tracts or cavities, and loosening of joint prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/3\">",
"     3",
"    </a>",
"    ]. Arthrography can also be performed using either computed tomography (CT arthrography) or magnetic resonance imaging (MR arthrography, using a dilute gadolinium solution). Standard arthrography is particularly helpful for the &nbsp;\"real time\" tracking of contrast as it passes through and fills the joint thereby highlighting specific abnormalities.",
"   </p>",
"   <p>",
"    Complications of arthrography are few, the most common being synovial irritation (chemical synovitis) induced by the iodinated contrast agent, urticaria, and vasovagal reaction. Infection is very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional tomography utilizes reciprocal motion of the X-ray source and film about a fulcrum. The motion may be linear or a more complex pattern that effectively blurs structures above and below the fulcrum. A two-dimensional planar image is produced at a selected depth in the tissue. By varying the orientation of the body part, the imaged plane can be altered. Raising or lowering the table will change the level imaged. This technique has largely been replaced by CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography has become an invaluable diagnostic aid in the evaluation of the musculoskeletal system. Utilizing a rotating x-ray source in the axial plane, attenuation values are computer processed to produce a cross-sectional image. Post-acquisition data processing allows for far greater latitude concerning image display as compared with radiography. Equipment with a single linear array of detectors or with multiple arrays of detectors (MDCT) may be used.",
"   </p>",
"   <p>",
"    Air-filled spaces, fatty tissue, muscle, and cortical and cancellous bone may all be evaluated with a single CT acquisition. Images may be displayed to best demonstrate soft tissues or bones. In contrast to radiography, complicated bony structures and complex pathological processes are displayed with clarity and without being obscured by superimposed structures. CT is, for example, extremely useful in detecting radiographically occult fractures of the acetabulum, cervical spine, wrist, and foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Helical (spiral) CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helical CT involves continuous patient translation through the gantry at a constant rate during x-ray source rotation and data acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/11\">",
"     11",
"    </a>",
"    ]. A volume set of data is, therefore, obtained in a relatively short period of time, often in a single breath hold. Helical CT results in decreased artifacts due to motion, and respiratory misregistration as well as applications such as CT angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/12\">",
"     12",
"    </a>",
"    ]. These improved techniques have lead to increased utilization.",
"   </p>",
"   <p>",
"    It is essential to carefully review the indications for each examination and minimize the radiation dose as much as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/13\">",
"     13",
"    </a>",
"    ] particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manipulation of the imaging data allows high quality multiplanar reformations and three-dimensional displays to be created at a workstation. This is particularly useful in evaluating skeletal trauma, surgical planning, and in identifying relationships between structures and between fracture fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/16\">",
"     16",
"    </a>",
"    ]. Fractures of the acetabulum are particularly well suited to CT evaluation given the complex anatomy inherent to this structure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the absolute resolution of CT is less than radiography, CT is superior in resolving subtle cortical disease. Small cortical or subchondral fractures and osteochondral intraarticular bodies are better seen on CT than radiographs.",
"   </p>",
"   <p>",
"    CT imaging also has benefits compared with magnetic resonance imaging (MRI). As an example, soft tissue calcifications and bony abnormalities are better characterized with CT, although MRI is superior for soft tissue contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/18\">",
"     18",
"    </a>",
"    ]. The CT exam requires less time and tends to be less alarming to claustrophobic patients. The presence of metallic implants or pacemakers and the use of life support equipment (eg, ventilators) does not preclude the use of CT, whereas some of these devices are contraindications to MR scanning (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Contraindications to MRI'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Technical advances, including manipulating x-ray generating voltage (kVp) and current (mA), have reduced the artifacts produced by metallic implants so that the bone and soft tissue near the hardware can be examined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/19\">",
"     19",
"    </a>",
"    ]. In one series, retrospective evaluation of multidetector CT scanning for determining the presence of orthopedic hardware complications was performed in 109 patients (114 studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/20\">",
"     20",
"    </a>",
"    ]. Clinical or operative follow-up in 80 percent of cases provided the reference standard. The sensitivity and specificity of this imaging technique in patients with follow-up were 74 percent and 95 percent, respectively. CT was considerably better than plain film radiography for the detection of these complications.",
"   </p>",
"   <p>",
"    Multidetector CT scanning (MDCT) is also useful for the determination of joint fusion following arthrodesis. A retrospective study, MDCT was used to correlate the degree of osseous fusion visualized on the CT scan with the clinical finding of joint stability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/21\">",
"     21",
"    </a>",
"    ]. A total of 42 consecutive MDCT examinations from 29 patients with ankle or subtalar joint fusions were assessed and clinical judgement of fusion stability was used as the reference. A threshold value for the ratio of CT images (each a 2mm slice) demonstrating fusion to the total number of slices of 33 percent was suggested as indicative of stability of the fused joint [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT is frequently utilized for the purposes of guiding bone and soft tissue biopsy and aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI depicts internal structures based upon their chemical composition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/23\">",
"     23",
"    </a>",
"    ]. A major advantage of MRI is its ability to evaluate non-calcified body tissues. For example, menisci, articular cartilage, cruciate ligaments and joint fluid, which would be indistinguishable on a radiograph, are readily distinguished on MRI. MRI is very sensitive in detecting subtle changes in the water content of tissues due to inflammation, neoplasm, trauma, or ischemia. A more detailed discussion of MRI is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principle of MRI is that when a patient is placed in the bore of a super conducting electromagnet, free hydrogen nuclei within the tissues will align their inherent magnetic dipoles with that of the magnetic field. This creates a new atomic low energy state. Rapid pulses of radio-frequency electromagnetic radiation are then imparted to the tissues, which deflect the spinning nuclei off their axes, creating a higher energy state. As the nuclei return to their baseline state, they emit electromagnetic energy that varies in intensity based on chemical composition. The energy released by the nuclei relaxing to their baseline energy level can be localized in space, quantified, and a cross-sectional image of the body produced.",
"   </p>",
"   <p>",
"    MRI systems are available in several field strengths; high-field magnets (&gt;1.0 Tesla [T]), mid-field magnets (0.5-1.0T) and low-field magnets (&lt;0.5T). Some advantages of higher field strength are increased signal to noise (providing higher spatial resolution), shorter image acquisition times and improved imaging after intravenous contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/24\">",
"     24",
"    </a>",
"    ]. Whole body open magnet systems provide greater ease in patient positioning, can be used for larger patients, and decrease claustrophobia. However, these magnets are often low- or mid-field with limited signal to noise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another type of MR system utilizes extremity magnets. Extremity magnets are often low-field magnets that generally allow imaging of peripheral joints. Claustrophobia is avoided since only the part to be examined is placed within the magnet's bore. The use of these low-field extremity magnets for imaging rheumatoid arthritis has been a topic of ongoing discussion, especially since these magnets are small enough to be located in an office or clinic.",
"   </p>",
"   <p>",
"    Extremity MRI is more sensitive than plain film radiography for the detection of joint erosions. This was illustrated in a study of 44 patients that noted four times as many erosions with extremity MRI than with radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/25\">",
"     25",
"    </a>",
"    ]. The authors of the study concluded that imaging both hands can be used as a screening tool and that examining one hand can be used to monitor erosions over time.",
"   </p>",
"   <p>",
"    Changes within the medullary space of bone alter the normal marrow signal and are depicted with great clarity by MRI. Thus, conditions such as avascular necrosis, transient regional osteoporosis, early infections, subtle trauma, ischemia, and infiltrative processes are best visualized using MRI.",
"   </p>",
"   <p>",
"    The periarticular soft tissues such as the ligaments, tendons, muscles, synovium, and cartilage are directly visualized and readily evaluated with MRI. An infinite number of reconstruction planes allow for the sagittal, coronal, and axial display of these complex structures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Normal tendons are completely black (low signal) on traditional MRI sequences. Tendons in early stages of degeneration demonstrate abnormal (increased) signal and contour alterations, and complete disruptions are often easily identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contraindications to MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several contraindications to MRI including the presence of [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Orbital metallic foreign bodies",
"     </li>",
"     <li>",
"      Cardiac pacemakers or implanted defibrillators",
"     </li>",
"     <li>",
"      Cochlear implants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is a valuable tool used to evaluate obstetric and fetal diseases. At this time, there is no evidence of harmful effects to the fetus. However, concern remains about the safety of MRI during pregnancy, particularly in regard to the heating effects of the radiofrequency pulses and acoustic noise on the fetus. It is advised to obtain written informed consent for MRI in the pregnant patient to document the patient's understanding of alternative diagnostic options, risk-benefit ratios, and to inform them that there are no known harmful effects at clinical imaging field strengths of 1.5 T and below.",
"   </p>",
"   <p>",
"    However, avoiding imaging pregnant patients with field strengths in excess of 2.5 T is prudent due to lack of experience with magnetic fields of this strength in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metallic prostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of joint prosthetic devices are perfectly safe, although larger metallic objects, such as joint prostheses, may distort the MRI image. Nonetheless, with appropriate technical parameters, MR imaging may actually be used to assess complications of joint replacement. This was illustrated by an evaluation of 46 total knee prostheses (41 patients) using an MRI technique tailored to reduce metal susceptibility artifact resulted in surgical or other therapeutic procedures in 20 patients and influenced treatment in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     MR Guided Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the superior soft tissue contrast resolution inherent to MRI, it is not surprising that MR guided biopsy has evolved as a tool to obtain tissue diagnosis for both bone and soft tissue lesions. With the use of special instrumentation, it has been found that MR guidance is feasible for biopsies, spine procedures, cyst aspirations, therapeutic injections, and tumor ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/31\">",
"     31",
"    </a>",
"    ]. As MR becomes increasingly available it is likely that it will also become increasingly used for these purposes. By combining fluoroscopy with MR to form hybrid systems, the advantages of each system can be utilized in a synergistic way [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     MR arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of a dilute solution of gadolinium into a joint produces an MR arthrogram that allows the intraarticular structures (such as cartilage surfaces) to be defined and increases the ability to detect adjacent ligamentous or tendinous disruptions. MR arthrography is often used in evaluating the shoulder and the hip for labral tears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indirect MR arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;After intravenous administration, gadolinium contrast material will also diffuse into joints, even normal ones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/32\">",
"     32",
"    </a>",
"    ]. This diffusion can be utilized to provide an \"intravenous arthrogram\" which can be helpful in delineating articular cartilage and other intraarticular structures. An increased rate of diffusion of contrast will occur in patients with active inflammatory arthritis (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Rheumatoid arthritis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Concerns expressed below regarding toxicity when used in patients with advance renal failure apply to intravenous MR arthrography. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Potential gadolinium toxicity in renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intravenous contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenously administered contrast agents, such as gadolinium, highlight vascular structures and may make some pathologic processes more conspicuous. MRI contrast agents reflect tissue vascularity and perfusion. In general, malignant soft tissue tumors show greater and more rapid contrast enhancement than benign lesions, although differentiation of benign from malignant lesions is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/33\">",
"     33",
"    </a>",
"    ]. Avascular, necrotic, and cystic areas will not show enhancement. Therefore, when there is a question of whether a lesion is solid or cystic, intravenous contrast can be helpful. (This distinction can also be made with ultrasound). Intravenous contrast is also used in evaluating bone tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Potential gadolinium toxicity in renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderately or severely impaired renal function (eg, estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    should avoid gadolinium-containing MRI contrast agents due to an enhanced risk of developing nephrogenic systemic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H22#H22\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR imaging demonstrates all of the structures that may be involved in osteoarthritis including the subchondral bone, articular cartilage, menisci, ligaments, and synovium. Currently, MRI is most often used as a research tool in osteoarthritis. One osteoarthritis scoring system, BLOKS (Boston-Leeds Osteoarthritis Knee Score), uses MRI to evaluate nine intraarticular regions of the knee and measures features of bone marrow lesions, cartilage, osteophytes, synovitis, effusions, and ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/34\">",
"     34",
"    </a>",
"    ]. However, further epidemiological studies are required and the role of MRI in clinically diagnosed osteoarthritis is still being clarified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI may be used to quantify articular cartilage and display it as a three-dimensional surface rendered image [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/27\">",
"     27",
"    </a>",
"    ]. Evaluation of cartilage volumes in 107 OA patients at baseline, 12 and 24 months was done by Raynauld et al [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/36\">",
"     36",
"    </a>",
"    ]. Determination of cartilage volume loss allowed identification of patients who were slow, intermediate or fast progressors. Clinical factors (such as a high body mass index) and morphological factors (such as severe meniscal extrusion) were predictors of rapid progression. In addition to the volume of articular cartilage, the structure of cartilage can be studied with MRI. Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) uses quantitative T1 mapping of articular cartilage after intravenous injection and penetration of gadolinium to assess the distribution of glycosaminoglycans (GAG) in articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/37\">",
"     37",
"    </a>",
"    ]. Protocols to assess the entire knee at 1.5 or 3 T have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cartilage Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthopedic techniques are being developed and refined to repair",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replace damaged cartilage. Two such techniques are autologous chondrocyte implantation (ACI) and microfracture, and these are employed principally at the knee. &nbsp;Short-term results of the two techniques appear comparable in terms of macroscopic and histologic results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI has the ability to assess the integrity of these cartilage repair sites [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/39\">",
"     39",
"    </a>",
"    ]. This was illustrated in a study that used delayed gadolinium-enhanced MRI (dGEMRIC) at 3 Tesla to evaluate two groups of 10 patients each who had undergone ACI and microfracture, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;At a mean time from surgery of 17 months there was a statistically significant increase in the relative glycosaminoglycan (GAG) content within the ACI group as compared with the microfracture patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial hypertrophy, erosive disease, small subchondral cysts, and subchondral bone marrow edema not observed on radiographs can be visualized on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/41\">",
"     41",
"    </a>",
"    ]. In one study of 31 patients with early rheumatoid arthritis who had swelling of the metacarpophalangeal joints, MRI detected bone marrow edema in 21 patients compared with 3 of 31 healthy control subjects. Synovial enhancement patterns can indicate active versus inactive RA. However, it has been noted that there is \"...currently no consensus regarding when high field MRI should be ordered for the diagnosis and management of RA\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NUCLEAR MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear or scintigraphic images are produced following the administration of a radiopharmaceutical agent, which distributes in the body based upon its chemical and biological properties. Radiation emitted from the agent is converted into planar or tomographic images. The unique aspect of scintigraphy is that radiotracer localization provides image contrast and is based on both tissue physiology and anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the type of nuclear study, disease processes may manifest as areas of increased or decreased activity. As an example, an abnormality of the myocardium will be photopenic or \"cold\" on a stress-perfusion scan, while a metabolically active focus of lymphomatous tissue may be active or \"hot\" on a gallium scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful nuclear imaging examination to evaluate joint processes is the bone scan. To perform a bone scan, a Tc 99m labeled organophosphate (such as Tc99m MDP) is injected intravenously. These compounds preferentially bind to hydroxyapatite moieties in bone. Differential binding has been suggested to be due to one or more of several mechanisms including the amount of osteoid formation, blood flow, &nbsp;mineralization of osteoid, or sympathetic nerve supply [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone scans have a high sensitivity for detecting fracture, infection, tumor, and metabolic bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/44\">",
"     44",
"    </a>",
"    ]. A negative study effectively eliminates most bony abnormalities. Occasionally, however, the disease process may be photopenic or even normal in some cases of multiple myeloma, aggressive tumors, or osteomyelitis. In these settings, there is essentially no new bone formation to preferentially bind the radiopharmaceutical [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain disorders demonstrate characteristic features on bone scan imaging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute fracture commonly accumulates radiopharmaceutical in a linear fashion at the site of injury.",
"     </li>",
"     <li>",
"      Osteoid osteoma avidly collects the bone-imaging agent in a focal area surrounded by a rim of less intense uptake. When this benign bone tumor is located intraarticularly, the uptake may be less intense than for extraarticular lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paget disease, fibrous dysplasia, and melorheostosis demonstrate intense activity, which may be multi-focal in the long bones or axial skeleton. When viewed in conjunction with radiographs, a diagnosis can be made. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteomyelitis can be diagnosed with a positive \"three-phase bone scan\" in an appropriate clinical setting. A positive \"three-phase bone scan\" demonstrates increased radionuclide activity in all three phases: blood flow phase, blood pool phase, and delayed uptake at the area in question. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\", section on 'Three phase bone scan'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic pulmonary osteoarthropathy and shin splints have a periosteal distribution of activity.",
"     </li>",
"     <li>",
"      Complex regional pain syndrome (also known as reflex sympathetic dystrophy and other terms), which is often occult on other radiologic modalities, may demonstrate intense periarticular activity in an involved extremity on the delayed phase of the scan preceded by hyperemia in a similar distribution on the immediate post-injection blood flow and blood pool phases of the scan [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings noted on a bone scan, however, may lack specificity in certain clinical settings. As an example, although a patient with a history of advanced breast carcinoma and multiple foci of increased isotope uptake throughout the axial skeleton almost certainly has bony metastatic disease, the differential diagnosis of a single focus of increased activity in the distal femur is lengthy, ranging from osteoarthritis to malignancy.",
"   </p>",
"   <p>",
"    In addition to the standard bone scan agent, Tc99m-MDP, other radiopharmaceuticals may be employed for specific clinical questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labeled WBC's or gallium 67 may accumulate in sites of infection with a greater degree of specificity. This can be of help in evaluating joint replacements.",
"     </li>",
"     <li>",
"      Thallium 201 is concentrated by many tumors. Although it is a less sensitive imaging agent than Tc99m-MDP, the loss of thallium accumulation in a given tumor over time is associated with a good response to chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET scan) is a diagnostic examination that involves the acquisition of physiologic images based on the detection of two gamma photons traveling in opposite directions. These photons are generated from the annihilation of a positron with a native electron. It is the positron-emitting radionuclides that are tagged to metabolically active pharmaceuticals and administered to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET scanning performed with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) provides qualitative and quantitative metabolic information [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/49\">",
"     49",
"    </a>",
"    ]. FDG is a radiopharmaceutical analog of glucose that is taken up by metabolically active cells such as tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/49\">",
"     49",
"    </a>",
"    ]. PET scans are capable of demonstrating abnormal metabolic activity before abnormal morphologic changes have occurred and can be helpful in distinguishing benign from malignant tumors.",
"   </p>",
"   <p>",
"    PET-CT involves the simultaneous acquisition of both metabolic (PET) and anatomic (CT) information which is then combined for presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/49\">",
"     49",
"    </a>",
"    ]. Analysis is done by visual inspection and calculation of SUV's (standardized uptake value of a tissue at a single point in time) to provide a semiquantitative measure of tracer uptake.",
"   </p>",
"   <p>",
"    PET-CT scanning is typically used in the detection and follow-up of tumors such as solitary pulmonary nodules, non-small cell lung carcinoma, lymphoma, melanoma, breast and colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     PET scanning in arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;FDG PET (18 fluorodeoxyglucose positron emission tomography) has been investigated for assessing the metabolic activity of rheumatoid synovitis. Sixteen patients with active rheumatoid arthritis were assessed with 18F-FDG PET dynamic contrast enhanced MRI, ultrasound, C- reactive protein and serum metalloproteinase-3 before and four weeks after treatment with anti-TNF-alpha. PET-positive knees showed higher MRI parameters and greater synovial thickness than negative knees. Standardized uptake values (SUV's) correlated with all MRI parameters, synovial thickness, serum CRP and MMP-3 levels at baseline and with these parameters (except synovial thickness) at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another area of concern in patients with rheumatoid arthritis is the atlantoaxial joint. Atlantoaxial instability may result in patients with rheumatoid arthritis. Radiographic evaluation of the cervical spine is often used to detect dynamic instability by comparing the atlantoaxial relationship between flexion and extension radiographs in the lateral projection. A recent investigation utilizing",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    of the whole body in patients with rheumatoid arthritis was able to detect areas of active inflammation. More importantly,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was able to detect active inflammation in areas that were not yet causing clinical symptoms. Detecting active inflammation at the atlantoaxial joint before clinical symptoms develop may be a determinant of future instability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound images are produced by the sequential emission and reception of sound waves in the range of 2.0 to 12.0 MHz by a piezoelectric crystal. The crystal will vibrate when stimulated by an alternating voltage source and is able to transmit sound waves into a medium in contact with its surface. The same crystal is able to generate a voltage signal when its surface is subjected to mechanical deformation by the returning echoes.",
"   </p>",
"   <p>",
"    An ultrasound probe sequentially transmits and receives sound waves, with a larger percentage of time devoted to the receiving mode. Computer processing of several lines of echo data yields a grey-scale, cross-sectional image. The sound waves may be electronically focused at a chosen tissue depth, but the information will ultimately fade as depth limitations are reached.",
"   </p>",
"   <p>",
"    Ultrasonography is an important tool to evaluate the pediatric hip and to detect effusion in children presenting with hip pain. Ultrasound has also been used to evaluate both inflammatory arthritis and osteoarthritis. In the knee, ultrasonography can detect synovitis. In one study, 60 patients with knee pain were examined both clinically and ultrasonographically and the results were compared to arthroscopic findings as the \"gold standard\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/52\">",
"     52",
"    </a>",
"    ]. In comparison to arthroscopy, US demonstrated &nbsp;synovitis in the knee with sensitivity and specificity of 98 percent and 88 percent, respectively.",
"   </p>",
"   <p>",
"    These test characteristics were better than the performance of the clinical assessment for synovitis. Power Doppler ultrasonography has been used to examine synovial vascularity and, therefore, arthritis activity and correlates with MR imaging findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the technical difficulties described earlier, bone abnormalities in general are difficult to study using ultrasound. However, ultrasonography has been used to detect osseous erosion in inflammatory arthritis. Correlation of ultrasonographic findings with MRI as the reference standard for bone erosion in metacarpophalangeal (MCP) and proximal interphalangeal joints of 40 patients with MRI and 20 controls showed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensitivity = 59 percent",
"     </li>",
"     <li>",
"      Specificity = 98 percent",
"     </li>",
"     <li>",
"      Accuracy = 96 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was greater sensitivity than radiography with comparable specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The detection of increased vascularity in the synovium is important in suggesting the presence of synovitis. The addition of ultrasound contrast agent (typically consisting of injected microbubbles) may increase the conspicuousness of increased vascularity that can occur with synovitis. In a study of patients with rheumatoid arthritis who had both joint swelling and tenderness, the addition of ultrasound contrast agent was able to detect increased vascularity in 80 percent of these patients while power Doppler evaluation alone detected increased vascularity in only 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/56\">",
"     56",
"    </a>",
"    ] However, the added cost of the contrast agent and the time required to obtain intravenous access are factors to consider before adopting ultrasound contrast agents.",
"   </p>",
"   <p>",
"    Enthesopathy is a term used to describe abnormalities at the enthesis (insertion site of a tendon on bone). Enthesopathy may be caused by a variety of etiologies, including inflammatory and degenerative arthropathy, metabolic diseases, and trauma. With ultrasound, it is possible to evaluate the enthesis for signs of enthesopathy and when combined with power Doppler US may even be able to distinguish inflammatory arthropathy from simple degenerative change [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography is almost universally available, is less expensive than CT or MRI, and utilizes no ionizing radiation. Use in the office setting is feasible, although there are insufficient data upon which to base recommendations regarding adequate training and appropriate indications for use of musculoskeletal ultrasonography by non-radiologists. Recommendations based on expert opinion of a group of radiologists and rheumatologists with expertise in ultrasonography suggest that with education and training in the basic principles of ultrasonography, available ultrasonographic equipment, and techniques of visualizing joints, tendons, bones, and bursae, this imaging techniques may be useful for rheumatologists to perform for the following indications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment and monitoring of inflammatory arthritis",
"     </li>",
"     <li>",
"      Imaging tendons and bursae",
"     </li>",
"     <li>",
"      Guiding aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      injection of joints or soft tissues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two fundamental limitations of ultrasonography remain:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Since sound waves have poor soft tissue penetration and are completely reflected by bone, there are limited acoustic windows for imaging joint pathology.",
"     </li>",
"     <li>",
"      Ultrasonography is extremely operator dependent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When utilized, the ultrasound study should be a targeted examination, such as to exclude a possible tendon tear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/59\">",
"     59",
"    </a>",
"    ]. Tendons have a characteristic hyperechoic and homogeneous appearance, and tendonitis or frank tendon rupture can be diagnosed as a change in echotexture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a generalized joint survey is not recommended, imaging of the contralateral joint is helpful for comparison purposes as many findings may be subtle. Skin edema, soft tissue collections, bursae, and joint effusions are readily observed. The shoulder, knee, and ankle are the more commonly studied regions for tendon disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs remain the imaging study of choice for routine evaluation of fractures, inflammatory and degenerative arthritides, infiltrative disorders, metabolic bone disease, and developmental deformities. CT scanning may be useful in detecting cortical bony lesions and is widely used in fracture detection especially in complex areas such as the cervical spine. Internal derangement of a joint and soft tissue injuries are best evaluated with MRI. Nuclear medicine studies should be reserved for situations where previous imaging studies are negative but there remains a strong clinical suspicion of bony abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3193/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. PET scanning has become an important method for evaluating the metabolic activity of tumors.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/1\">",
"      Algorithms for the diagnosis and management of musculoskeletal complaints. Am J Med 1997; 103:49S.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology: Appropriateness Criteria. file://www.acr.org/Quality-Safety/Appropriateness-Criteria/Diagnostic/Musculoskeletal-Imaging (Accessed on May 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/3\">",
"      Dalinka MK, Kricun ME, Zlatkin MB, Hibbard CA. Modern diagnostic imaging in joint disease. AJR Am J Roentgenol 1989; 152:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/4\">",
"      Phillips AC, Polisson RP. The rational initial clinical evaluation of the patient with musculoskeletal complaints. Am J Med 1997; 103:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/5\">",
"      Gallet J, Titus H. CR/DR systems: what each technology offers today; what is expected for the future. Radiol Manage 2005; 27:30.",
"     </a>",
"    </li>",
"    <li>",
"     Direct radiography. www.henkenind.com/direct_radiography.htm (Accessed September 9, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/7\">",
"      Reiner BI, Siegel EL, Hooper FJ, et al. Multi-institutional analysis of computed and direct radiography: part I. Technologist productivity. Radiology 2005; 236:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/8\">",
"      Choplin RH, Gilula LA, Murphy WA. Fluoroscopic evaluation of skeletal problems. Skeletal Radiol 1981; 7:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/9\">",
"      Helgason JW, Chandnani VP, Yu JS. MR arthrography: a review of current technique and applications. AJR Am J Roentgenol 1997; 168:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/10\">",
"      Newberg AH, Munn CS, Robbins AH. Complications of arthrography. Radiology 1985; 155:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/11\">",
"      Heiken JP, Brink JA, Vannier MW. Spiral (helical) CT. Radiology 1993; 189:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/12\">",
"      Brink JA, Heiken JP, Wang G, et al. Helical CT: principles and technical considerations. Radiographics 1994; 14:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/13\">",
"      Wiest PW, Locken JA, Heintz PH, Mettler FA Jr. CT scanning: a major source of radiation exposure. Semin Ultrasound CT MR 2002; 23:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/14\">",
"      Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics 2003; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/15\">",
"      Brody AS, Frush DP, Huda W, et al. Radiation risk to children from computed tomography. Pediatrics 2007; 120:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/16\">",
"      Geijer M, El-Khoury GY. MDCT in the evaluation of skeletal trauma: principles, protocols, and clinical applications. Emerg Radiol 2006; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/17\">",
"      Geijer M, El-Khoury GY. Imaging of the acetabulum in the era of multidetector computed tomography. Emerg Radiol 2007; 14:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/18\">",
"      Conway WF, Totty WG, McEnery KW. CT and MR imaging of the hip. Radiology 1996; 198:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/19\">",
"      Moon SG, Hong SH, Choi JY, et al. Metal artifact reduction by the alteration of technical factors in multidetector computed tomography: a 3-dimensional quantitative assessment. J Comput Assist Tomogr 2008; 32:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/20\">",
"      Ohashi K, El-Khoury GY, Bennett DL, et al. Orthopedic hardware complications diagnosed with multi-detector row CT. Radiology 2005; 237:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/21\">",
"      Dorsey ML, Liu PT, Roberts CC, Kile TA. Correlation of arthrodesis stability with degree of joint fusion on MDCT. AJR Am J Roentgenol 2009; 192:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/22\">",
"      Hau A, Kim I, Kattapuram S, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/23\">",
"      Prost R, Czervionke LF. How does an MR scanner operate? AJNR Am J Neuroradiol 1994; 15:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/24\">",
"      American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. Extremity magnetic resonance imaging in rheumatoid arthritis: report of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. Arthritis Rheum 2006; 54:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/25\">",
"      Olech E, Freeston JE, Conaghan PG, et al. Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. J Rheumatol 2008; 35:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/26\">",
"      Heron CW. Magnetic resonance imaging in rheumatology. Ann Rheum Dis 1992; 51:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/27\">",
"      McCauley TR, Disler DG. MR imaging of articular cartilage. Radiology 1998; 209:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/28\">",
"      Shellock FG, Morisoli S, Kanal E. MR procedures and biomedical implants, materials, and devices: 1993 update. Radiology 1993; 189:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/29\">",
"      Patel SJ, Reede DL, Katz DS, et al. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. Radiographics 2007; 27:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/30\">",
"      Sofka CM, Potter HG, Figgie M, Laskin R. Magnetic resonance imaging of total knee arthroplasty. Clin Orthop Relat Res 2003; :129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/31\">",
"      Smith KA, Carrino J. MRI-guided interventions of the musculoskeletal system. J Magn Reson Imaging 2008; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/32\">",
"      Winalski CS, Aliabadi P, Wright RJ, et al. Enhancement of joint fluid with intravenously administered gadopentetate dimeglumine: technique, rationale, and implications. Radiology 1993; 187:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/33\">",
"      Kransdorf MJ, Murphey MD. Soft tissue tumors: post-treatment imaging. Radiol Clin North Am 2006; 44:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/34\">",
"      Hunter DJ, Lo GH, Gale D, et al. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). Ann Rheum Dis 2008; 67:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/35\">",
"      Conaghan P. Is MRI useful in osteoarthritis? Best Pract Res Clin Rheumatol 2006; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/36\">",
"      Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006; 8:R21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/37\">",
"      McKenzie CA, Williams A, Prasad PV, Burstein D. Three-dimensional delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at 1.5T and 3.0T. J Magn Reson Imaging 2006; 24:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/38\">",
"      Knutsen G, Engebretsen L, Ludvigsen TC, et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am 2004; 86-A:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/39\">",
"      Tins BJ, McCall IW, Takahashi T, et al. Autologous chondrocyte implantation in knee joint: MR imaging and histologic features at 1-year follow-up. Radiology 2005; 234:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/40\">",
"      Trattnig S, Mamisch TC, Pinker K, et al. Differentiating normal hyaline cartilage from post-surgical repair tissue using fast gradient echo imaging in delayed gadolinium-enhanced MRI (dGEMRIC) at 3 Tesla. Eur Radiol 2008; 18:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/41\">",
"      Backhaus M, Kamradt T, Sandrock D, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 1999; 42:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/42\">",
"      Alazraki NP. Diagnosing prosthetic joint infection. J Nucl Med 1990; 31:1955.",
"     </a>",
"    </li>",
"    <li>",
"     Mettler, FA, Guiberteau, MJ. Essentials of nuclear medicine imaging, Saunders/Elsevier, Philadelphia, PA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/44\">",
"      Tumeh SS. Scintigraphy in the evaluation of arthropathy. Radiol Clin North Am 1996; 34:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/45\">",
"      Ludwig H, Kumpan W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol 1982; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/46\">",
"      Szendroi M, K&ouml;llo K, Antal I, et al. Intraarticular osteoid osteoma: clinical features, imaging results, and comparison with extraarticular localization. J Rheumatol 2004; 31:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/47\">",
"      Nadel HR. Bone scan update. Semin Nucl Med 2007; 37:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/48\">",
"      Sato O, Kawai A, Ozaki T, et al. Value of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci 1998; 3:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/49\">",
"      Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/50\">",
"      Beckers C, Jeukens X, Ribbens C, et al. (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 2006; 33:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/51\">",
"      Kubota, K, Ito, K, Morooka, M, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Annals of Nuclear Medicine 2009; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/52\">",
"      Karim Z, Wakefield RJ, Quinn M, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 2004; 50:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/53\">",
"      Kiris A, Ozgocmen S, Kocakoc E, Ardicoglu O. Power Doppler assessment of overall disease activity in patients with rheumatoid arthritis. J Clin Ultrasound 2006; 34:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/54\">",
"      Strunk J, Klingenberger P, Strube K, et al. Three-dimensional Doppler sonographic vascular imaging in regions with increased MR enhancement in inflamed wrists of patients with rheumatoid arthritis. Joint Bone Spine 2006; 73:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/55\">",
"      Szkudlarek M, Klarlund M, Narvestad E, et al. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: a comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthritis Res Ther 2006; 8:R52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/56\">",
"      Rees JD, Pilcher J, Heron C, Kiely PD. A comparison of clinical vs ultrasound determined synovitis in rheumatoid arthritis utilizing gray-scale, power Doppler and the intravenous microbubble contrast agent 'Sono-Vue'. Rheumatology (Oxford) 2007; 46:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/57\">",
"      Falsetti P, Acciai C, Lenzi L, Frediani B. Ultrasound of enthesopathy in rheumatic diseases. Mod Rheumatol 2009; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/58\">",
"      Brown AK, O'connor PJ, Roberts TE, et al. Recommendations for musculoskeletal ultrasonography by rheumatologists: setting global standards for best practice by expert consensus. Arthritis Rheum 2005; 53:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/59\">",
"      Barberie JE, Wong AD, Cooperberg PL, Carson BW. Extended field-of-view sonography in musculoskeletal disorders. AJR Am J Roentgenol 1998; 171:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3193/abstract/60\">",
"      Misamore GW, Woodward C. Evaluation of degenerative lesions of the rotator cuff. A comparison of arthrography and ultrasonography. J Bone Joint Surg Am 1991; 73:704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6921 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3193=[""].join("\n");
var outline_f3_7_3193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPUTED TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Helical (spiral) CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAGNETIC RESONANCE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contraindications to MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metallic prostheses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MR Guided Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MR arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indirect MR arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intravenous contrast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Potential gadolinium toxicity in renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cartilage Repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NUCLEAR MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PET scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PET scanning in arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_7_3194="Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment";
var content_f3_7_3194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Diane Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Evelyn Attia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/7/3194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/7/3194/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/7/3194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29336273\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa is characterized by an abnormally low body weight, intense fear of gaining weight, distorted perception of body weight and shape, and amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. The term &ldquo;anorexia&rdquo; is a misnomer because patients often retain their appetite.",
"   </p>",
"   <p>",
"    Anorexia nervosa is more common in women than men; one study estimated that the lifetime prevalence of anorexia nervosa in women is 0.9 percent and in men is as high as 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2\">",
"     2",
"    </a>",
"    ]. The disorder has been recognized for hundreds of years across different cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis, associated clinical features, differential diagnosis, comorbid psychopathology, and assessment of anorexia nervosa are reviewed here. The epidemiology, pathogenesis, medical complications, treatment, and outcome of anorexia nervosa are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"       \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30982?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173811834\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) and the World Health Organization's International Classification of Diseases-10th Revision (ICD-10) can each be used to diagnose anorexia nervosa. We suggest using the DSM-IV-TR criteria; however, the two sets of criteria are largely the same.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173811841\">",
"    <span class=\"h2\">",
"     Diagnostic and Statistical Manual, Fourth Edition, Text Revision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A DSM-IV-TR diagnosis of anorexia nervosa requires each of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refusal to maintain body weight at or above a minimally normal weight for age and height (eg, &lt;85 percent of expected body weight)",
"     </li>",
"     <li>",
"      Intense fear of gaining weight or becoming fat despite being underweight",
"     </li>",
"     <li>",
"      Distorted perception of body weight and shape, undue influence of weight and shape on self-worth, or denial of the medical seriousness of one&rsquo;s low body weight",
"     </li>",
"     <li>",
"      In postmenarchal females, amenorrhea (ie, absence of at least three consecutive menstrual cycles).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no single standard for what constitutes a minimally normal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Determining whether body weight is abnormally low depends upon individual factors such as body frame, skeletal structure, and racial ethnicity. DSM-IV-TR suggests that a minimally normal weight is equal to 85 percent of expected weight for age and height, but this guideline is not required. Most clinicians use standardized tables such as the Metropolitan Life Insurance Height-Weight Tables created in 1983 to obtain normal adult weight for height (",
"    <a class=\"graphic graphic_table graphicRef71826 \" href=\"UTD.htm?10/14/10477\">",
"     table 2",
"    </a>",
"    ). These are actuarial tables developed to predict the longest lifespan [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Alternatively, ICD-10 includes a stricter guideline based upon body mass index (BMI). (See",
"    <a class=\"local\" href=\"#H173811848\">",
"     'International Classification of Diseases - 10th Revision'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients lose weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintain a low body weight in various ways that typically include reducing total food intake [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may begin by excluding highly caloric foods, but dietary restraint usually leads to a restricted diet that is sometimes limited to only a few foods. Patients may also fast for a day or longer and exercise excessively such that it interferes with important activities, or occurs at inappropriate times, in inappropriate settings, or despite injury. In addition, patients may purge, ie, induce vomiting or misuse laxatives, diuretics, or enemas. Purging with laxatives, diuretics, or enemas does not rid the body of unwanted calories, but does cause a temporary loss of bodily fluids that may result in a lower measured weight and feeling of relief [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/8\">",
"     8",
"    </a>",
"    ]. Self-induced vomiting is also associated with significant retention of calories. Medical complications of purging are discussed separately within the context of bulimia nervosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link&amp;anchor=H27959316#H27959316\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Medical complications of bulimia nervosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fear of gaining weight or becoming fat usually does not abate with weight loss; rather, the fear often increases despite continued weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Disturbed body image manifests in different ways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients believe they are overweight, while others are concerned that specific body parts are fat. As a result, patients may excessively weigh themselves, measure body parts, or view themselves in a mirror. In addition, self-esteem depends upon body weight and shape; weight loss is viewed as an achievement and sign of self-discipline, whereas weight gain is a failure of self-control. Patients may concede that they are emaciated, but usually deny the medical complications of starvation. Most authorities view distorted body image as an overvalued idea rather than a delusion, even when the distortion is expressed as a false, fixed belief [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Anorexia nervosa usually causes a functional hypothalamic amenorrhea in postmenarchal females, characterized by low levels of luteinizing hormone and follicle-stimulating hormone (despite low estrogen levels) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, a number of authorities dispute the necessity of this criterion for diagnosing anorexia nervosa, and many studies do not require amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H278931821#H278931821\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Hypothalamus and pituitary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DSM-IV-TR describes two subtypes of anorexia nervosa, restricting and",
"    <span class=\"nowrap\">",
"     binge-eating/purging",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. The restricting subtype is characterized by dieting or excessive exercise, and the absence of regular binge-eating (eating an amount of food that is definitely larger than most people would eat under similar circumstances) or purging during the current episode of anorexia nervosa. The",
"    <span class=\"nowrap\">",
"     binge-eating/purging",
"    </span>",
"    subtype is characterized by episodes of binge-eating or purging at least once per week. Crossover between the two subtypes of anorexia nervosa occurs often, especially from the restricting subtype to the",
"    <span class=\"nowrap\">",
"     binge/purge",
"    </span>",
"    subtype; this raises questions about their predictive validity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who meet some but not all of the diagnostic criteria for anorexia nervosa are given the diagnosis of eating disorder not otherwise specified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, menstruating women who meet the other three criteria for anorexia nervosa should be diagnosed with eating disorder not otherwise specified. (See",
"    <a class=\"local\" href=\"#H173812577\">",
"     'Eating disorder not otherwise specified'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173811848\">",
"    <span class=\"h2\">",
"     International Classification of Diseases - 10th Revision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD-10 diagnostic criteria for anorexia nervosa overlap considerably with the DSM-IV-TR criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. An ICD-10 diagnosis of anorexia nervosa requires all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body weight is maintained at least 15% below that expected, or BMI (ratio of weight in kg divided by height in m",
"      <sup>",
"       2",
"      </sup>",
"      ) &le;17.5 (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Weight loss is self-induced by avoiding \"fattening foods\" and one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Self-induced vomiting",
"     </li>",
"     <li>",
"      Self-induced purging with laxatives",
"     </li>",
"     <li>",
"      Misuse of diuretics&nbsp;",
"     </li>",
"     <li>",
"      Misuse of appetite suppressants&nbsp;",
"     </li>",
"     <li>",
"      Excessive exercise&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distortion of body-image; a dread of fatness persists as an intrusive, overvalued idea; and patients impose a low weight threshold upon themselves&nbsp;",
"     </li>",
"     <li>",
"      An endocrine disorder involving the hypothalamic-pituitary-gonadal axis manifests in women as amenorrhoea and in men as a loss of sexual interest and potency. (An exception is the persistence of vaginal bleeds in anorexic women who are receiving replacement hormonal therapy.) There may also be elevated levels of growth hormone and cortisol, changes in the peripheral metabolism of the thyroid hormone, and abnormal insulin secretion.&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29336301\">",
"    <span class=\"h1\">",
"     ASSOCIATED CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the core clinical features of low body weight, intense fear of gaining weight, distorted perception of body weight and shape, and amenorrhea, anorexia nervosa is typically accompanied by other psychological and behavioral features, as well as medical complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29336317\">",
"    <span class=\"h2\">",
"     Psychological and behavioral features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological and behavioral signs and symptoms associated with anorexia nervosa include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relentless pursuit of thinness",
"     </li>",
"     <li>",
"      Obsessional preoccupation with food (eg, collecting recipes or hoarding food)",
"     </li>",
"     <li>",
"      Fear of certain foods",
"     </li>",
"     <li>",
"      Restricted repertoire of foods",
"     </li>",
"     <li>",
"      Preference for low calorie foods (low energy density)",
"     </li>",
"     <li>",
"      Overestimating number of calories consumed",
"     </li>",
"     <li>",
"      Overusing condiments",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      artificially sweetened products",
"     </li>",
"     <li>",
"      Food-related rituals (eg, cutting food into small pieces or refusing to mix different types or colors of food on the plate)",
"     </li>",
"     <li>",
"      Concerns about eating in public",
"     </li>",
"     <li>",
"      Social withdrawal",
"     </li>",
"     <li>",
"      Exercise-related rituals (eg, walking or running a set distance each day; swimming a specified number of laps in a pool)",
"     </li>",
"     <li>",
"      Restlessness or hyperactivity",
"     </li>",
"     <li>",
"      Limited insight into or denial of core clinical features",
"     </li>",
"     <li>",
"      Resistance to treatment and weight gain",
"     </li>",
"     <li>",
"      Inhibited expression of emotions",
"     </li>",
"     <li>",
"      Feelings of ineffectiveness",
"     </li>",
"     <li>",
"      Inflexible thinking",
"     </li>",
"     <li>",
"      Perfectionism",
"     </li>",
"     <li>",
"      Need to control one&rsquo;s environment",
"     </li>",
"     <li>",
"      Behavioral rigidity (eg, purchasing food only in certain stores or from certain salespeople, inability to accommodate to changes in schedule or environment)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these features can persist in weight-restored patients with anorexia nervosa, reflecting either problems that predated onset of the eating disorder or long-term &ldquo;scars&rdquo; caused by starvation.",
"   </p>",
"   <p>",
"    Anorexia nervosa is often accompanied by additional psychopathology, including suicidality and depressive, anxiety, substance use, impulse control, and personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H549367471\">",
"     'Comorbid psychopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935824\">",
"    <span class=\"h3\">",
"     Males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa occurs significantly more often in females than males [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2\">",
"     2",
"    </a>",
"    ], but the clinical features for the two sexes are generally similar. One study of 99 patients hospitalized for anorexia nervosa found little difference between males and females in their core clinical symptoms and comorbid disorders and personality traits, except that the concern for weight manifested by males was significantly less than that for females [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935755\">",
"    <span class=\"h2\">",
"     Medical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common physical signs in anorexia nervosa include emaciation, hypothermia, bradycardia, hypotension, hypoactive bowel sounds, xerosis (dry, scaly skin), brittle hair, and hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Many of these abnormalities are probably caused by starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In addition, many patients with anorexia nervosa induce vomiting after eating, which can erode dental enamel and cause hypertrophy of the parotid glands and &ldquo;puffy&rdquo; cheeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1,18,19\">",
"     1,18,19",
"    </a>",
"    ]. Regular vomiting can also cause dehydration, hypokalemia, hypochloremia, and metabolic alkalosis. Common physical signs, medical evaluation, and medical complications of anorexia nervosa and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link&amp;anchor=H86793557#H86793557\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\", section on 'Common physical signs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    .) Medical complications of self-induced vomiting are discussed separately within the context of bulimia nervosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link&amp;anchor=H27959316#H27959316\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Medical complications of bulimia nervosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29336352\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa is the most common cause of substantial weight loss in young adolescent females in western countries, and the diagnosis is often clear because patients present with emaciation in conjunction with self-induced starvation and intense fear of fatness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4\">",
"     4",
"    </a>",
"    ]. However, specific symptoms of anorexia nervosa (eg, weight loss) may overlap with symptoms of other psychiatric and medical illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Patients with these other illnesses are generally concerned about their weight loss and do not restrict their diet or exercise excessively; in addition, body image is usually not distorted. Some of the illnesses that resemble anorexia nervosa can also occur in conjunction with anorexia nervosa (eg, unipolar major depression). (See",
"    <a class=\"local\" href=\"#H549367471\">",
"     'Comorbid psychopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367377\">",
"    <span class=\"h2\">",
"     Eating disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173812569\">",
"    <span class=\"h3\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulimia nervosa and anorexia nervosa are both marked by overvaluation of body shape and weight. In addition, patients with bulimia nervosa binge eat and purge, as do many patients with anorexia nervosa. Making the correct diagnosis is essential for treatment.",
"   </p>",
"   <p>",
"    The key distinguishing feature of anorexia nervosa is an abnormally low body weight typically less than 85 percent of what is expected for the patient&rsquo;s age and height. By contrast, patients with bulimia nervosa usually maintain a body weight at or above a minimally normal level [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. Secondarily, the low weight that occurs in anorexia nervosa is accompanied by anatomic and physiologic sequelae that are not found in bulimia nervosa. Additional information about the differential diagnosis between anorexia nervosa and bulimia nervosa and their medical complications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H258842622#H258842622\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Anorexia nervosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173812577\">",
"    <span class=\"h3\">",
"     Eating disorder not otherwise specified",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient meets some but not all of the diagnostic criteria for anorexia nervosa, the diagnosis is eating disorder not otherwise specified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, an observational study described 20 patients with &ldquo;atypical anorexia nervosa&rdquo; who were severely malnourished and amenorrheic with no other identified psychiatric or medical cause for their weight loss, but who otherwise acknowledged their emaciation and denied fear of weight gain and distorted perception of their body weight and shape [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, there are a number of females with regular menses who otherwise meet all of the diagnostic criteria for anorexia nervosa (some authorities diagnose such patients as anorexia nervosa). Another example is an obese patient who demonstrates the signs and symptoms of anorexia nervosa during rapid weight loss to a normal weight. Additional information about eating disorder not otherwise specified is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link&amp;anchor=H5#H5\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Eating disorder not otherwise specified'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with clinically meaningful symptoms of anorexia nervosa that do not rise to the level of meeting criteria for the diagnosis are nevertheless treated for the disorder. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15204758\">",
"    <span class=\"h2\">",
"     Other psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific symptoms of anorexia nervosa are similar to symptoms that occur in [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Unipolar major depression",
"      </strong>",
"      &ndash; Decreased weight often occurs in major depressive disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"       1",
"      </a>",
"      ]. However, the weight loss in major depression is due to loss of appetite and is not intentional, and reluctance to gain weight and distorted body image are not present. In addition, depressed patients are usually anergic; by contrast, anorexia nervosa patients often exercise excessively.",
"     </li>",
"     <li>",
"      <strong>",
"       Social phobia",
"      </strong>",
"      &ndash; Patients with either social phobia or anorexia nervosa may be embarrassed to eat in public. However, patients with social phobia recognize that the fear is excessive or unreasonable, and they are not emaciated.",
"     </li>",
"     <li>",
"      <strong>",
"       Obsessive-compulsive disorder",
"      </strong>",
"      &ndash; Obsessions and compulsions regarding food can occur in both anorexia nervosa and obsessive-compulsive disorder. However, patients with obsessive-compulsive disorder are not emaciated and recognize that the preoccupations and behaviors are excessive or unreasonable.",
"     </li>",
"     <li>",
"      <strong>",
"       Body dysmorphic disorder",
"      </strong>",
"      &ndash; Patients with anorexia nervosa may be excessively preoccupied with an imagined defect in body appearance, as occurs in body dysmorphic disorder. However, the preoccupation in anorexia nervosa concerns body weight (&ldquo;fatness&rdquo;) or shape, whereas in body dysmorphic disorder the imagined defect typically involves the face or head. In addition, body dysmorphic disorder does not manifest with emaciation and a fear of becoming fat.",
"     </li>",
"     <li>",
"      <strong>",
"       Psychotic disorders",
"      </strong>",
"      &ndash; Psychotic patients may have delusions about food (eg, food is poisoned), refuse to eat, and lose weight. In contrast to anorexia nervosa, these psychotic disorders usually do not include fear of gaining weight or distorted body image.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Attention-Deficit/Hyperactivity",
"       </strong>",
"      </span>",
"      Disorder",
"      &ndash; Restlessness and impaired concentration are common to both",
"      <span class=\"nowrap\">",
"       ADD/ADHD",
"      </span>",
"      and anorexia nervosa. However, in anorexia nervosa, these symptoms are typically due to low weight and improve with normalization of body weight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening for comorbid disorders and their diagnostic criteria are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367385\">",
"    <span class=\"h2\">",
"     Medical disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis of anorexia nervosa is not clear, the medical evaluation should account for other nonpsychiatric medical illnesses that can present with weight loss, malabsorption, or secondary amenorrhea. These include neoplasm, chronic infections, uncontrolled diabetes mellitus, hyperthyroidism, malabsorption syndromes, inflammatory bowel disease, pregnancy, primary ovarian failure, polycystic ovary disease, and pituitary prolactinoma (",
"    <a class=\"graphic graphic_table graphicRef69495 \" href=\"UTD.htm?8/61/9181\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59801 \" href=\"UTD.htm?1/19/1340\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73995 \" href=\"UTD.htm?25/25/26012\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link&amp;anchor=H86793571#H86793571\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\", section on 'Excluding medical disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367471\">",
"    <span class=\"h1\">",
"     COMORBID PSYCHOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric comorbidity is common among patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26\">",
"     26",
"    </a>",
"    ]. However, many comorbid disorders are secondary to the eating disorder and resolve with weight restoration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/27\">",
"     27",
"    </a>",
"    ]. This is especially true for comorbid major depression, which is frequent but rarely accompanied by melancholia or psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4\">",
"     4",
"    </a>",
"    ]. The implication is that treatment should initially focus upon anorexia nervosa and suicidality. Following remission, the patient should be reassessed for any comorbidities requiring treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/1\">",
"     1",
"    </a>",
"    ]. Severe substance use disorder is the one exception, which should be prioritized to manage withdrawal phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H2#H2\">",
"     \"Eating disorders: Treatment\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367601\">",
"    <span class=\"h2\">",
"     Suicidality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa is often accompanied by suicidality, including suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reviews estimate that 8 to 27 percent of anorexia nervosa patients have a lifetime history of attempted suicide [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. A subsequent study of 432 patients with anorexia nervosa found that 17 percent had attempted suicide [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, impulsive nonfatal self-harm (eg, cutting or burning with a lit cigarette) is often seen.",
"     </li>",
"     <li>",
"      A longitudinal follow-up of 177 patients with anorexia nervosa (mean 18 years), using a computerized death index database, found that one percent committed suicide, which was nearly five times the rate in the general population (standardized mortality ratio 4.7, 95 percent CI 0.1-26.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study, which interviewed 136 patients with anorexia nervosa every 6 to 12 months and searched the National Death Index for patients deemed out of contact, found that three percent committed suicide; this was 57 times the rate in the general population (standardized mortality ratio 57, 95 percent CI 15-146) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with anorexia nervosa, comorbid substance use disorders and a history of sexual abuse are often associated with suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/28-30,33-35\">",
"     28-30,33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with suicidality should be seen more frequently and perhaps hospitalized, depending upon the estimated level of risk (",
"    <a class=\"graphic graphic_table graphicRef73092 \" href=\"UTD.htm?9/54/10094\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A specific suicide plan of high lethality or intent indicates the need for hospitalization. Risk factors, evaluation, and management of suicidality are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367609\">",
"    <span class=\"h2\">",
"     Axis I disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the specific rate of comorbid axis I disorders differs between epidemiologic surveys and studies in clinical settings, there is general agreement that patients with anorexia nervosa often suffer from [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2,36\">",
"     2,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorders",
"     </li>",
"     <li>",
"      Mood disorders",
"     </li>",
"     <li>",
"      Substance use disorders",
"     </li>",
"     <li>",
"      Impulse control disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening for comorbid disorders and their diagnostic criteria are discussed separately.",
"   </p>",
"   <p>",
"    A comorbid anxiety or mood disorder is diagnosed if it clearly preceded onset of the episode of anorexia nervosa, or if the anxiety or depressive symptoms are not explained by starvation and not related to the eating disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, compulsive counting of caloric intake and expenditure is better conceptualized as a feature of anorexia nervosa, whereas compulsive checking of locks is better thought of as a feature of comorbid obsessive-compulsive disorder.",
"   </p>",
"   <p>",
"    Most patients with anorexia nervosa have a lifetime history of at least one comorbid axis I disorder (",
"    <a class=\"graphic graphic_table graphicRef57877 \" href=\"UTD.htm?18/37/19037\">",
"     table 7",
"    </a>",
"    ). A nationally representative epidemiologic survey in the United States estimated that 56 percent of patients with anorexia nervosa had a lifetime history of at least one comorbid axis I disorder, and that 34 percent had three or more comorbid disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2\">",
"     2",
"    </a>",
"    ]. Anxiety disorders were most common and found in 48 percent of patients with anorexia nervosa; this is similar to the finding that 55 percent of patients treated at academically-affiliated eating disorder clinics have a lifetime history of at least one comorbid anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/36\">",
"     36",
"    </a>",
"    ]. Unipolar major depression appears to be the most prevalent comorbid disorder, regardless of setting. The lifetime rates for these comorbidities in patients with anorexia nervosa exceed the rates in the general population. As an example, the estimated lifetime prevalence of unipolar major depression in the general population is 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/37\">",
"     37",
"    </a>",
"    ]. Shared etiologic factors may account for some of the observed comorbidity involving anxiety and depressive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/23,38\">",
"     23,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Onset of anorexia nervosa often begins prior to the onset of comorbid mood or substance use disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2,39\">",
"     2,39",
"    </a>",
"    ]. Conversely, comorbid anxiety or impulse control disorders usually predate anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/2,40\">",
"     2,40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The association between comorbid axis I disorders and the prognosis for anorexia nervosa depends upon the specific comorbid disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Comorbid substance use disorder can adversely affect treatment outcome for eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, increased severity of comorbid alcohol use disorder is associated with increased mortality in anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/32\">",
"     32",
"    </a>",
"    ]. By contrast, the relationship between comorbid depressive or anxiety disorders and prognosis for anorexia nervosa is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26,43\">",
"     26,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367617\">",
"    <span class=\"h2\">",
"     Personality disorders and traits",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of comorbid personality disorders and traits can occur in anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26\">",
"     26",
"    </a>",
"    ], and more than one disorder or trait can occur in the same patient. Diagnosis of a comorbid personality disorder rests upon the patient&rsquo;s history prior to onset of anorexia nervosa, given that anorexia nervosa can affect the patient&rsquo;s cognitions, emotions, and interpersonal functioning. &nbsp;",
"   </p>",
"   <p>",
"    In a review of six studies that used diagnostic interviews, the most common personality disorders in patients with anorexia nervosa were [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/44\">",
"     44",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obsessive-compulsive (15 percent of patients with anorexia nervosa)",
"     </li>",
"     <li>",
"      Avoidant (14 percent)",
"     </li>",
"     <li>",
"      Dependent (7 percent)",
"     </li>",
"     <li>",
"      Narcissistic (6 percent)",
"     </li>",
"     <li>",
"      Paranoid (4 percent)",
"     </li>",
"     <li>",
"      Borderline (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent study that used diagnostic interviews in 49 patients with anorexia nervosa found that 51 percent met criteria for at least one personality disorder, including avoidant (31 percent of patients), paranoid (20 percent), obsessive-compulsive (18 percent), dependent (18 percent), borderline (10 percent), and narcissistic (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification, diagnosis, and treatment of personality disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with anorexia nervosa may also have comorbid traits that are not severe enough to meet criteria for a personality disorder, but nevertheless cause distress and impair functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26,44\">",
"     26,44",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perfectionism &ndash; pursuing unrealistically high standards despite the occurrence of adverse consequences",
"     </li>",
"     <li>",
"      Compulsivity &ndash; insisting upon order, symmetry, exactness, and control",
"     </li>",
"     <li>",
"      Narcissism &ndash; craving admiration and external validation from others; excessive concern with physical appearance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic significance of comorbid personality disorders and traits is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29336359\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation of patients with a possible diagnosis of anorexia nervosa includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The clinical interview may be augmented with a self-report screening measure and a structured interviewing instrument. The initial assessment should address the diagnostic criteria, associated clinical features, comorbid psychopathology, and medical complications of anorexia nervosa, and may require multiple interviews [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26\">",
"     26",
"    </a>",
"    ]. Subsequently, the clinician should monitor the patient&rsquo;s response to treatment and assess the patient for new illnesses.",
"   </p>",
"   <p>",
"    Many patients with anorexia nervosa are not forthcoming about their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. Symptoms of anorexia nervosa are often ego-syntonic, and thus the patient&rsquo;s presenting complaint may be anxiety, depression, or somatic discomfort due to medical complications such as pain with eating, bloating, or &ldquo;inability to keep food down.&rdquo; In addition, some patients are ashamed of the disorder, and may attempt to conceal their thinness by wearing bulky clothes and may inflate their body weight by hiding objects in their clothes and drinking water [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/19\">",
"     19",
"    </a>",
"    ]. Denial of the illness may delay assessment until family members or friends are compelled to obtain psychiatric and medical care for the patient.",
"   </p>",
"   <p>",
"    Establishing rapport with the patient can help elicit more information. At the beginning of the interview, simple questions about the patient&rsquo;s age, occupation, marital status, and referral source can put the patient at ease. In addition, directed and focused questions about eating disorder psychopathology may be helpful for patients who do not respond to open-ended questions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/49\">",
"     49",
"    </a>",
"    ]. Conveying a nonjudgmental, supportive, and knowledgeable attitude also helps. Collateral information should be sought from family members, who may report the presence of vomitus in the house, finding laxatives or diuretics, or the patient regularly departing to the bathroom after meals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should also evaluate the patient&rsquo;s medical status [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Assessing and managing the medical complications of anorexia nervosa are discussed separately. (See",
"    <a class=\"local\" href=\"#H935755\">",
"     'Medical complications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367253\">",
"    <span class=\"h2\">",
"     Screening instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic interview can be facilitated by first administering a self-report screening instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients who screen positive for an eating disorder should be asked about the DSM-IV-TR diagnostic criteria for anorexia nervosa and bulimia nervosa. Self-report instruments can save interviewer time, but are more prone to yielding false positives than clinician-administered instruments. (See",
"    <a class=\"local\" href=\"#H173811841\">",
"     'Diagnostic and Statistical Manual, Fourth Edition, Text Revision'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H88601455#H88601455\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Diagnostic and Statistical Manual, Fourth Edition, Text Revision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the available self-report measures that screen for eating disorders, we suggest the five-item SCOFF, which is discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link&amp;anchor=H14#H14\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Screening tools'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367632\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation should assess [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26,53,54\">",
"     26,53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Height and weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Current body weight and desired weight. Clinicians should measure weight and height as well as ask about them because the patient&rsquo;s self-report is often unreliable. Body mass index (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and percent ideal body weight (",
"      <a class=\"graphic graphic_table graphicRef71826 \" href=\"UTD.htm?10/14/10477\">",
"       table 2",
"      </a>",
"      ) should then be determined for comparison to population norms.",
"     </li>",
"     <li>",
"      Recent weight changes, lifetime highest and lowest weights at adult height, stability of weight over time, and history of efforts to control weight and shape. A chronology should be established to",
"      <strong>",
"      </strong>",
"      determine whether current symptoms are acute or chronic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequency of self-weighing",
"     </li>",
"     <li>",
"      Meal pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Estimate typical daily caloric intake (both foods and beverage) and assess pattern of consumption, including times, amounts, and context",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Present and past eating disorder symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dietary restriction",
"     </li>",
"     <li>",
"      Attitudes about food, eating, body weight, and shape (including fear of becoming fat and resistance to gaining weight)",
"     </li>",
"     <li>",
"      Binge eating",
"     </li>",
"     <li>",
"      Compensatory behaviors such as purging (self-induced vomiting or misuse of laxatives, diuretics, or enemas), fasting, and exercise",
"     </li>",
"     <li>",
"      Ritualistic eating behaviors (eg, cutting food into extremely small pieces or refusing to mix different types or colors of food on the plate)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Last menstrual period",
"     </li>",
"     <li>",
"      Regularity of menses",
"     </li>",
"     <li>",
"      Weight at which spontaneous menses occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prescription medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral contraceptives can produce withdrawal bleeding that simulates menstrual periods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suicidality",
"     </li>",
"     <li>",
"      Comorbid disorders, such as anxiety, mood, impulse control, substance use, and personality disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nicotine, caffeine, cocaine, and stimulants may be used to curb appetite",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial functioning",
"     </li>",
"     <li>",
"      Prior treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Psychotherapy",
"     </li>",
"     <li>",
"      Pharmacotherapy",
"     </li>",
"     <li>",
"      Self-help groups &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history of eating disorders and other psychopathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suicidality and comorbid disorders are discussed separately. (See",
"    <a class=\"local\" href=\"#H549367601\">",
"     'Suicidality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H549367471\">",
"     'Comorbid psychopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In discussing onset of anorexia nervosa, the clinician should ask about interpersonal problems at that time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/26\">",
"     26",
"    </a>",
"    ]. However, family members should not be blamed for causing the illness; there is no evidence that families cause eating disorders.",
"   </p>",
"   <p>",
"    As part of the mental status examination, the clinician should note behavioral restlessness or fidgeting. Impaired attention, concentration, and thought process can indicate cognitive impairment, including delirium related to medical complications of low weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    purging. Anxious or depressed affect should be assessed. Insight and judgment can be evaluated by asking about the patient&rsquo;s target weight and treatment-seeking behaviors.",
"   </p>",
"   <p>",
"    Medical complications of anorexia nervosa that can be found on history and physical examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link&amp;anchor=H86793536#H86793536\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\", section on 'Medical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367682\">",
"    <span class=\"h2\">",
"     Structured instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structured, interviewer-administered instruments are available for diagnosing anorexia nervosa and other eating disorders, but are seldom used in routine clinical practice. Structured instruments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H7789016#H7789016\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Structured instruments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549367755\">",
"    <span class=\"h2\">",
"     Measurement based care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that at each visit, clinicians weigh the patient wearing as little clothing as appropriate (eg, hospital gown) and after voiding. Clinicians should also ask about daily caloric intake, the number of hours spent exercising and walking each day, and the number of binge-eating and purging episodes that occurred each week since the last visit. Measurement based care can help identify nonresponders and detect residual symptoms. Symptomatic change over time can also be assessed with self-report measures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/55\">",
"     55",
"    </a>",
"    ], such as the 36-item Eating Disorder Examination Questionnaire (EDE-Q [",
"    <a class=\"abstract\" href=\"UTD.htm?3/7/3194/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=see_link\">",
"       \"Patient information: Anorexia nervosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29336514\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of anorexia nervosa according to the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"       table 1",
"      </a>",
"      ). The diagnostic criteria of the International Classification of Diseases-10th Revision (ICD-10) are largely the same. (See",
"      <a class=\"local\" href=\"#H173811841\">",
"       'Diagnostic and Statistical Manual, Fourth Edition, Text Revision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H173811848\">",
"       'International Classification of Diseases - 10th Revision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychological and behavioral features associated with anorexia nervosa include perfectionism, cognitive and behavioral rigidity, feelings of ineffectiveness, inhibited expression of emotions, social withdrawal, poor insight, resistance to treatment, restlessness or hyperactivity, as well as symptoms and signs related to food and eating, such as preoccupation with food and rituals related to meals. (See",
"      <a class=\"local\" href=\"#H29336317\">",
"       'Psychological and behavioral features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common physical signs in anorexia nervosa include emaciation, hypothermia, bradycardia, hypotension, hypoactive bowel sounds, dry skin, brittle hair, and hair loss. (See",
"      <a class=\"local\" href=\"#H935755\">",
"       'Medical complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although certain diagnostic criteria for anorexia nervosa and bulimia nervosa are the same, body weight is usually low in anorexia nervosa and normal in bulimia nervosa. The differential diagnosis for anorexia nervosa also includes other psychiatric and medical disorders, but these illnesses typically do not present with intentional weight loss or fear of gaining weight. (See",
"      <a class=\"local\" href=\"#H549367377\">",
"       'Eating disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15204758\">",
"       'Other psychiatric disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H549367385\">",
"       'Medical disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with anorexia nervosa are often suicidal and frequently have a lifetime history of comorbid psychiatric disorders, including anxiety, mood, impulse control, substance use, and personality disorders. Patients with suicidality should be seen more frequently and perhaps hospitalized, depending upon the estimated level of risk. A specific suicide plan of high lethality or intent indicates the need for hospitalization (",
"      <a class=\"graphic graphic_table graphicRef73092 \" href=\"UTD.htm?9/54/10094\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H549367601\">",
"       'Suicidality'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"       \"Suicidal ideation and behavior in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H549367609\">",
"       'Axis I disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H549367617\">",
"       'Personality disorders and traits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic interview can be facilitated by first administering a self-report instrument that screens for eating disorders. We suggest the five-item SCOFF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link&amp;anchor=H14#H14\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Screening tools'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H549367253\">",
"       'Screening instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial clinical evaluation should assess height, weight, meal patterns, present and past eating disorder symptoms (dietary restriction; attitudes about body weight and shape, food, and eating; binge eating; compensatory behaviors such as purging, fasting, and exercise; and ritualistic eating behaviors), menstrual status, suicidality, comorbid psychiatric disorders, psychosocial functioning, and family psychiatric history. (See",
"      <a class=\"local\" href=\"#H549367632\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should weigh patients at each visit and ask about daily caloric intake, the number of hours spent exercising each day, and the number of binge-eating and purging episodes that occurred each week since the last visit. (See",
"      <a class=\"local\" href=\"#H549367755\">",
"       'Measurement based care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/2\">",
"      Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     Keel PK, McCormick L. Diagnosis, assessment, and treatment planning for anorexia nervosa. In: TheTreatment of Eating Disorders: A Clinical Handbook, Grilo CM, Mitchell JE (Eds), The Guilford Press, New York 2010. p.3.",
"    </li>",
"    <li>",
"     Andersen, AE, Yager, J. Eating disorders. In: Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Volume I, Ninth Edition, Sadock, BJ, Sadock, VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.2128.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/5\">",
"      1983 metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/6\">",
"      Pai MP, Paloucek FP. The origin of the \"ideal\" body weight equations. Ann Pharmacother 2000; 34:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/7\">",
"      Harrison GG. Height-weight tables. Ann Intern Med 1985; 103:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/8\">",
"      Kaye WH, Weltzin TE, Hsu LK, et al. Amount of calories retained after binge eating and vomiting. Am J Psychiatry 1993; 150:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/9\">",
"      Doufas AG, Mastorakos G. The hypothalamic-pituitary-thyroid axis and the female reproductive system. Ann N Y Acad Sci 2000; 900:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/10\">",
"      Vyver E, Steinegger C, Katzman DK. Eating disorders and menstrual dysfunction in adolescents. Ann N Y Acad Sci 2008; 1135:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/11\">",
"      Attia E, Roberto CA. Should amenorrhea be a diagnostic criterion for anorexia nervosa? Int J Eat Disord 2009; 42:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/12\">",
"      Roberto CA, Steinglass J, Mayer LE, et al. The clinical significance of amenorrhea as a diagnostic criterion for anorexia nervosa. Int J Eat Disord 2008; 41:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/13\">",
"      Eddy KT, Keel PK, Dorer DJ, et al. Longitudinal comparison of anorexia nervosa subtypes. Int J Eat Disord 2002; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/14\">",
"      Eddy KT, Dorer DJ, Franko DL, et al. Diagnostic crossover in anorexia nervosa and bulimia nervosa: implications for DSM-V. Am J Psychiatry 2008; 165:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/15\">",
"      Peat C, Mitchell JE, Hoek HW, Wonderlich SA. Validity and utility of subtyping anorexia nervosa. Int J Eat Disord 2009; 42:590.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/17\">",
"      Strober M, Freeman R, Lampert C, et al. Are there gender differences in core symptoms, temperament, and short-term prospective outcome in anorexia nervosa? Int J Eat Disord 2006; 39:570.",
"     </a>",
"    </li>",
"    <li>",
"     Mehler, PS, Anderson, AE. Eating Disorders: A guide to medical care and complications, 2nd ed, The Johns Hopkins University Press, Baltimore, MD 2010.",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, Jahraus, JP. Medical complications of eating disorders. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/20\">",
"      Walsh BT, Devlin MJ. Eating disorders: progress and problems. Science 1998; 280:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/21\">",
"      S&ouml;dersten P, Nerg&aring;rdh R, Bergh C, et al. Behavioral neuroendocrinology and treatment of anorexia nervosa. Front Neuroendocrinol 2008; 29:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/22\">",
"      FRANKLIN JC, SCHEILE BC. Observations on human behavior in experimental semi-starvation and rehabilitation. J Clin Psychol 1948; 4:28.",
"     </a>",
"    </li>",
"    <li>",
"     Devlin, MJ, Jahraus, JP, DiMarco, ID. Eating disorders. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine, Second Edition, Levenson, JL (Eds), American Psychiatric Publishing, Inc, Washington, DC 2011. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/24\">",
"      Strober M, Freeman R, Morrell W. Atypical anorexia nervosa: separation from typical cases in course and outcome in a long-term prospective study. Int J Eat Disord 1999; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     Eating Disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa, and related eating disorders.",
"National Clinical Practice Guideline Number CG9 file://guidance.nice.org.uk/CG9/Guidance/pdf/English (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association, Practice Guideline for the Treatment of Patients With Eating Disorders, Third Edition, 2006 file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on February 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/27\">",
"      Meehan KG, Loeb KL, Roberto CA, Attia E. Mood change during weight restoration in patients with anorexia nervosa. Int J Eat Disord 2006; 39:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/28\">",
"      Franko DL, Keel PK. Suicidality in eating disorders: occurrence, correlates, and clinical implications. Clin Psychol Rev 2006; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/29\">",
"      Sansone RA, Levitt JL. Self-harm behaviors among those with eating disorders: an overview. Eat Disord 2002; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/30\">",
"      Bulik CM, Thornton L, Pinheiro AP, et al. Suicide attempts in anorexia nervosa. Psychosom Med 2008; 70:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/31\">",
"      Crow SJ, Peterson CB, Swanson SA, et al. Increased mortality in bulimia nervosa and other eating disorders. Am J Psychiatry 2009; 166:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/32\">",
"      Keel PK, Dorer DJ, Eddy KT, et al. Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003; 60:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/33\">",
"      Franko DL, Keel PK, Dorer DJ, et al. What predicts suicide attempts in women with eating disorders? Psychol Med 2004; 34:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/34\">",
"      Fedorowicz VJ, Falissard B, Foulon C, et al. Factors associated with suicidal behaviors in a large French sample of inpatients with eating disorders. Int J Eat Disord 2007; 40:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/35\">",
"      Pompili M, Girardi P, Tatarelli G, et al. Suicide and attempted suicide in eating disorders, obesity and weight-image concern. Eat Behav 2006; 7:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/36\">",
"      Kaye WH, Bulik CM, Thornton L, et al. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 2004; 161:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/37\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/38\">",
"      Altman SE, Shankman SA. What is the association between obsessive-compulsive disorder and eating disorders? Clin Psychol Rev 2009; 29:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/39\">",
"      Fernandez-Aranda F, Pinheiro AP, Tozzi F, et al. Symptom profile of major depressive disorder in women with eating disorders. Aust N Z J Psychiatry 2007; 41:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/40\">",
"      Fern&aacute;ndez-Aranda F, Pinheiro AP, Thornton LM, et al. Impulse control disorders in women with eating disorders. Psychiatry Res 2008; 157:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/41\">",
"      Milos GF, Spindler AM, Buddeberg C, Crameri A. Axes I and II comorbidity and treatment experiences in eating disorder subjects. Psychother Psychosom 2003; 72:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/42\">",
"      Fichter MM, Quadflieg N, Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/43\">",
"      Raney TJ, Thornton LM, Berrettini W, et al. Influence of overanxious disorder of childhood on the expression of anorexia nervosa. Int J Eat Disord 2008; 41:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/44\">",
"      Cassin SE, von Ranson KM. Personality and eating disorders: a decade in review. Clin Psychol Rev 2005; 25:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/45\">",
"      Jordan J, Joyce PR, Carter FA, et al. Specific and nonspecific comorbidity in anorexia nervosa. Int J Eat Disord 2008; 41:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/46\">",
"      Grilo CM. Recent research of relationships among eating disorders and personality disorders. Curr Psychiatry Rep 2002; 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/47\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     Crow, SJ, Brandenburg, B. Diagnosis, assessment, and treatment planning for bulimia nervosa. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.28.",
"    </li>",
"    <li>",
"     Peterson, CB, Mitchell, JE. Self-report measures. In: Assessment of Eating Disorders, Mitchell, JE, Peterson, CB (Eds), New York 2005. p.98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/51\">",
"      Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: assessment of a new screening tool for eating disorders. BMJ 1999; 319:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/52\">",
"      Hill LS, Reid F, Morgan JF, Lacey JH. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43:344.",
"     </a>",
"    </li>",
"    <li>",
"     Assessment of Eating Disorders, Mitchell, JE, Peterson, CB (Eds), Guilford Publications, New York 2005.",
"    </li>",
"    <li>",
"     Peterson, CB. Conducting the diagnostic interview. In: Assessment of Eating Disorders, Mitchell, JE, Peterson, CB (Eds), Guilford Publications, New York 2005. p.32.",
"    </li>",
"    <li>",
"     Peterson CB, Mitchell JE. Self-report measures. In: Assessment of Eating Disorders, Mitchell JE, Peterson CB (Eds), Guilford Publications, New York 2005. p.98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/56\">",
"      Mond JM, Hay PJ, Rodgers B, et al. Validity of the Eating Disorder Examination Questionnaire (EDE-Q) in screening for eating disorders in community samples. Behav Res Ther 2004; 42:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/7/3194/abstract/57\">",
"      Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord 1994; 16:363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14704 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3194=[""].join("\n");
var outline_f3_7_3194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29336514\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29336273\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173811834\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173811841\">",
"      Diagnostic and Statistical Manual, Fourth Edition, Text Revision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173811848\">",
"      International Classification of Diseases - 10th Revision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29336301\">",
"      ASSOCIATED CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29336317\">",
"      Psychological and behavioral features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935824\">",
"      - Males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H935755\">",
"      Medical complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29336352\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367377\">",
"      Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173812569\">",
"      - Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173812577\">",
"      - Eating disorder not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15204758\">",
"      Other psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367385\">",
"      Medical disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549367471\">",
"      COMORBID PSYCHOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367601\">",
"      Suicidality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367609\">",
"      Axis I disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367617\">",
"      Personality disorders and traits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29336359\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367253\">",
"      Screening instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367632\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367682\">",
"      Structured instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549367755\">",
"      Measurement based care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29336514\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/7/9339\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/14/10477\" title=\"table 2\">",
"      Metropolitan Life Insurance Company height-weight tables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/61/9181\" title=\"table 3\">",
"      Major causes of weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/19/1340\" title=\"table 4\">",
"      Causes of amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/25/26012\" title=\"table 5\">",
"      HPO axis and amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10094\" title=\"table 6\">",
"      Level of care guidelines for patients with eating disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/37/19037\" title=\"table 7\">",
"      Comorbidity anorexia nervosa with other DSM-IV Axis I disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30982?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=related_link\">",
"      Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=related_link\">",
"      Bulimia nervosa in adults: Clinical features, diagnosis, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=related_link\">",
"      Patient information: Anorexia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_7_3195="Clues to severe AAT deficiency";
var content_f3_7_3195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications of severe alpha-1 antitrypsin deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Emphysema in a young individual (ie, less than or equal to 45 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphysema in a nonsmoker or minimal smoker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphysema characterized by predominant basilar changes on the chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A family history of emphysema and/or liver disease, especially unexplained cirrhosis or hepatoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical findings or history of panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical findings or history of unexplained chronic liver disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3195=[""].join("\n");
var outline_f3_7_3195=null;
var title_f3_7_3196="Differential dx overgrowth";
var content_f3_7_3196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of overgrowth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral gigantism (Sotos syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beckwith-Wiedemann syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        In childhood and adolescence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Endocrine disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peripheral precocious puberty (congenital adrenal hyperplasia and others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Growth hormone excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sex hormone deficiency or insensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial glucocorticoid deficiency (FGD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital total lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Non-endocrine disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial (Constitutional) tall stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exogenous obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klinefelter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        XYY syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marfan syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Homocystinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurofibromatosis Type I",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3196=[""].join("\n");
var outline_f3_7_3196=null;
var title_f3_7_3197="DDx of syndromes after BMT II";
var content_f3_7_3197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of specific clinical syndromes after stem cell transplantation - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preengraftment, &lt;3 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immediate postengraftment, 3 weeks to 3 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late postengraftment, &gt;3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Diarrhea/colitis",
"       </td>",
"       <td>",
"        Bacteria (Clostridium difficile, C. septicum), Candida",
"spp., drug toxicity, acute graft versus host disease (GVHD), bleeding,",
"infarction",
"       </td>",
"       <td>",
"        Bacteria (C. difficile, C. septicum), cytomegalovirus (CMV), enteroviruses, drug toxicity, acute GVHD, bleeding, infarction",
"       </td>",
"       <td>",
"        Epstein Barr virus (EBV) - rare drug toxicity, chronic GVHD, bleeding, infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"        CNS symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Localized",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, molds, Candida spp., stroke, drug toxicity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, toxoplasmosis, molds, tumor relapse, drug toxicity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, molds, progressive multifocal leukoencephalopathy (PML), tumor relapse, drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, herpes simplex virus (HSV), Candida spp., drug toxicity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Human herpesvirus (HHV)-6, CMV, Cryptococcus spp.,drug toxicity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Varicella zoster virus (VZV), drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Hepatitis",
"       </td>",
"       <td>",
"        Bacteria, HSV, chronic disseminated candidiasis, veno-occlusive disease (VOD), drug toxicity acute GVHD, conditioning regimen",
"       </td>",
"       <td>",
"        HSV,",
"CMV, HHV-6, Pneumocystis carinii (PCP), chronic disseminated",
"candidiasis, VOD, drug toxicity, acute GVHD, conditioning regimen",
"       </td>",
"       <td>",
"        Hepatitis B, C viruses, EBV, VZV, VOD, drug toxicity, chronic GVHD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Esophagitis",
"       </td>",
"       <td>",
"        Candida spp., HSV, drug toxicity",
"       </td>",
"       <td>",
"        CMV, drug toxicity",
"       </td>",
"       <td>",
"        Drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Hemorrhagic cystitis",
"       </td>",
"       <td>",
"        Adenovirus (rarely), cyclophosphamide toxicity",
"       </td>",
"       <td>",
"        CMV, adenovirus, cyclophosphamide toxicity",
"       </td>",
"       <td>",
"        BK virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Nephritis",
"       </td>",
"       <td>",
"        Bacteria",
"       </td>",
"       <td>",
"        CMV, adenovirus",
"       </td>",
"       <td>",
"        BK/JC viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Skin lesions",
"       </td>",
"       <td>",
"        Bacteria, HSV, Candida spp., molds, acute GVHD, drug toxicity",
"       </td>",
"       <td>",
"        Bacteria, Candida spp., molds, CMV, HHV-6, atypical mycobacteria, acute GVHD, drug toxicity",
"       </td>",
"       <td>",
"        VZV, molds, chronic GVHD, drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Ocular",
"       </td>",
"       <td>",
"        Candida spp., molds",
"       </td>",
"       <td>",
"        CMV, PCP, toxoplasmosis",
"       </td>",
"       <td>",
"        VZV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Bone marrow suppression",
"       </td>",
"       <td>",
"        CMV, HHV-6, graft failure, drug toxicity acute GVHD",
"       </td>",
"       <td>",
"        CMV, HHV-6, graft failure, drug toxicity, acute GVHD",
"       </td>",
"       <td>",
"        Parvovirus, CMV, HHV-6, graft failure, drug toxicity, chronic GVHD",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3197=[""].join("\n");
var outline_f3_7_3197=null;
var title_f3_7_3198="Acanthosis nigricans";
var content_f3_7_3198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 162px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classic hyperpigmented axillary lesion in acanthosis nigricans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Flier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3198=[""].join("\n");
var outline_f3_7_3198=null;
var title_f3_7_3199="Pulmonary angioscopy II";
var content_f3_7_3199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary angioscopy in chronic thromboemboli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angioscopic appearance of chronic thromboembolic disease showing multiple channels through a partially-occluding thrombus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_7_3199=[""].join("\n");
var outline_f3_7_3199=null;
